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Detailed below are the commonest abbreviations used in this thesis. 
T1DM- Type 1 Diabetes 
T2DM- Type 2 Diabetes 
DCCT- Diabetes Control and Complications Trial 
EDIC- Epidemiology of Diabetes Interventions and Complications  
NICE- National Institute of Clinical Excellence 
NSF- National Service Framework 
SHA- Strategic Health Authority 
QoF- Quality Outcomes Framework 
GMS- General Medical Services 
GP- General Practitioner 
GPwSI – GP with a special interest 
IHD- Ischaemic Heart Disease 
CVD- Cerebro-vascular Disease 
PVD- Peripheral Vascular Disease 
BP- Blood pressure 
HbA1c- Haemoglobin A1 concentration (DCCT aligned) 
IVDU- Intravenous drug User 
DM- Diabetes mellitus 
PCT- Primary Care Trust 
ADA – American Diabetes Association 
NHS – National Health Service 
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4. Aims 
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The delivery of diabetes care has changed significantly over the last 30 years; 
virtually all aspects of treatment have altered or progressed. The routine 
measurement of biochemical markers are being used to gauge this progress.  
This thesis aims to examine some of these changes on a “real-world” group of 
patients with type 1 diabetes (T1DM). Such changes have occurred and are derived 
from an evidence base of clinical trials in specially selected groups of volunteer 
patients. Although this can demonstrate the effect of these interventions, there 
always remains the question of whether the findings can be translated into practice 
with ‘real-world’ patients. 
The effects of such interventions, particularly those in diabetes care, may take years 
to be apparent. It is therefore difficult to study such things in a prospective way 
within the context of an MD thesis. Using a retrospective analysis of a large patient 
cohort, with T1DM, who have been attending the same diabetes clinic since its 
inception, it has been possible to examine some of the outcomes of these patients in 
view of the changes that have occurred in diabetes practice over the last 10 -15 
years. 
• Firstly a comparison is made between the patient cohort from the clinic and 
the trial population of the landmark diabetes study; the DCCT1. The study 
examines if the goals of the DCCT are achievable in a “real-world” group of 
patients, the results of which are given in chapter 8. 
• Tight glycaemic control has become central to diabetes care post-DCCT. 
Further interventional studies, albeit predominantly in patients with T2DM, 
have demonstrated the benefits of aggressive management of risk factors for 
cardiovascular disease in patients with diabetes. Subsequently aggressive 
management of hypertension and dyslipidaemia has become the standard 
practice in guidelines for the management of T1DM. The clinic cohort studied 
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in this thesis has lived through these changes and it has been possible to 
assess if the implementation of these guidelines, for the management of 
lipids, blood pressure and glycaemic control, has made any measurable 
difference; this is described in chapter 9. 
• Most T1DM care is delivered in an outpatient setting. However some patients 
with T1DM do require care as hospital inpatients. A comparison of the one 
day prevalence of diabetes patients in hospital in 1991 and 2003 is 
discussed in chapter 10.  This is particularly relevant given the increasing 
interest in diabetes inpatients2. 
• In our hospital practice we noted a further group of patient with T1DM that 
were frequent hospital inpatients. These patients, all of whom had problems 
associated with intravenous drug abuse, were followed-up and their 
outcomes reported in chapter 11. These patients pose significant problems 
and challenges for the inpatient diabetes team. 
This thesis therefore aims to examine how successful the implementation of major 
trial evidence and guideline is at achieving results in the “real-world” and reviews 
what factors may limit success. Outpatient diabetes care provides the majority of the 
work for patients with diabetes. However, inpatient diabetes care remains a 
significant issue. Diabetes patients frequently spend longer in hospital than patients 
without diabetes and this is examined and discussed. 
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5. Introduction 
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Diabetes mellitus is a common chronic disease with an increasing incidence and 
prevalence. Predominantly, this has occurred in type 2 diabetes (T2DM) a problem 
which is associated with increasingly sedentary lifestyles, weight gain and 
decreased regular exercise 3, 4. There have also been increases in the incidence and 
prevalence of type 1 diabetes (T1DM)5-8.Recent estimates have suggested and 
annual increase in incidence of ~3% per year in Europe9 and a potential doubling of 
new cases in children under 5 years old within the next 20 years10.  Patients with 
T1DM and T2DM can develop complications which in the long term result in 
increased morbidity and mortality and considerable resources from the healthcare 
systems caring for them. 
Microvascular disease in T1DM and T2DM, in the form of diabetic retinopathy, 
nephropathy and neuropathy may lead respectively to visual impairment and 
blindness, end-stage renal failure, dialysis and lower limb amputation as a result of 
ulceration and chronic infection. These issues have a significant impact on the 
patient and the healthcare-systems supporting them. Macrovascular disease, 
(Ischaemic heart disease (IHD), cerebro-vascular disease (CVD) and peripheral 
vascular disease (PVD)), occurs with greater prevalence in patients with T1DM and 
T2DM than in the non-diabetic population. Increasing numbers of patients with 
T1DM are surviving into old age and macrovascular disease is seen more frequently 
and consequently requires more support and management11-13.This thesis will 
discuss some aspects of these issues with relevance to patients who have T1DM.   
The management of any disease can vary depending on its setting and it is 
important to outline the many factors which have resulted in the system of care we 
now deliver to patients with T1DM.  This introduction will summarise how the 
recognition and treatment of hyperglycaemia improves the morbidity and mortality 
and how healthcare systems have adapted to delivering this care.  
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5.1 Historical Perspective  
The introduction of insulin injections into diabetes practice took place in 1923. It was 
discovered in Toronto during 1921-22 and the Nobel Prize was awarded to 
Frederick Banting and J.J.R. Macleod in 1923. There remains controversy over this 
award as both Banting and Macleod each immediately called for the recognition of 
the people they also felt should have been acknowledged. In Banting’s case this 
was Charles Best, a young science student, with whom he did the experimental 
work. While Professor Macleod announced he would share the award with J.B. 
Collip, a biochemist that joined the research in late 1921. The details of the 
discovery of insulin is a book in itself14 and it is more commonly accepted that the 
experimental work leading to the identification and isolation of insulin was done by 
Banting and Best. 
Diabetes has been recognised for thousands of years. The characterisation of the 
disease may usefully be described in periods; The Ancient period, The Diagnostic 
period and The Experimental period. 
 
The Ancient period: from ~1550 BC onwards. 
Ancient documents such as the Ebers papyrus, found in Thebes in 1862, 
documented many disease states, amongst which one that resembled diabetes was 
noticeable. Diabetes, as a term to describe a condition, was first used by Areteaus 
of Cappadocia in ~2nd century AD. It is a term from Ionian Greek and means ‘to run 
through’.  
The urine in patients with diabetes was noted to taste sweet as early as the 5th and 
6th century AD and was documented in Arabic texts in the 9th-11th centuries, 
particularly those of Avicenna, who describes such complications as gangrene and 
collapse of sexual function. 
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The Diagnostic Period- 16th Century onwards. 
In the 17th century, English physician Thomas Willis made reference to the 
sweetness of diabetic urine. Around this time Thomas Sydenham speculated that 
diabetes was a systemic disease arising in the blood, where ‘chyle’ was 
incompletely absorbed. In the 1776 a Liverpool physician named Matthew Dobson 
published his account of a series of experiments and observations on the urine and 
blood of one of his typical patients with diabetes, Peter Dickonson. This paper was 
groundbreaking; confirming that urine was sweet to taste but also the serum taken 
from the patients’ blood tasted sweet, thus discovering hyperglycaemia. Such an 
observation helped divert diabetes research towards a study of how the body deals 
with carbohydrate foods15. 
 
The Experimental Period – 19th Century onwards.  
During this period, Claude Bernard (left) 
and Paul Langerhans (below) 
demonstrated how the liver stored 
glucose as glycogen16, and how the 
pancreas contained cells that did not 
appear to be concerned with its’ digestive 
secretions17. In 1889 Oskar Minkowski 
and colleagues performed a 
pancreatectomy on a dog to determine if 
digestion of fats could still occur. As an 
unintended side-effect they rendered the 
dog diabetic. This was confirmed on repeated study. Further experiments with 
ligated pancreatic ducts showed that the digestive secretion was not responsible for 
Claude Bernard 
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blood sugar control. An internal secretion of the 
pancreas had this role18, 19. Around 1900 Georg 
Ludwig Zuelzer discovered that pancreas extract 
reduced the sugar excreted in the urine of two 
diabetic dogs. Encouraged by this discovery, in 1906 
he twice injected a dying diabetic man with pancreas 
extract, and although no sugar measurements were 
made, the patient came out of the coma and his 
appetite returned14. Unfortunately there was no more pancreas extract to use and 
the patient subsequently died. By 1913 many people were interested in diabetes 
research. Indeed J.J.R Macleod a noted physiologist published Diabetes: Its 
Pathological Physiology. He concluded that there was an internal secretion of the 
pancreas, but suggested several reasons why it might never be captured in 
pancreatic extract. Researchers continued to work on pancreatic extract, including 
Israel Kleiner a young American working at the Rockefeller Institute and Nicholas 
Paulesco, professor of physiology at the Romanian 
School of Medicine, both had their work interrupted 
by the war, his findings in 1920 and also 
demonstrated a fall in blood sugar after injection of 
pancreas extract into dogs. Whilst this work 
continued, Frederick Banting had qualified as a 
surgeon from the University of Toronto in 1917. He 
was also involved in the Great War, not returning 
home until 1919 He opened a doctors’ office in 1920. During late October 1920 he 
prepared a talk on carbohydrate metabolism and read an article entitled: “The 
relation of the Islets of Langerhans to Diabetes with special reference to cases of 
pancreatic lithiasis” by Moses Barron. It struck Banting that the pancreatic 
degeneration that occurred during chronic lithiasis could be created by Paulesco 
Professor JJR Macleod 
Paul Langerhans 
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had to halt his research in 1916, until resumption in 1919. He published his findings 
in 1920 and also demonstrated a fall in blood sugar after injection of pancreas 
extract into dogs. Whilst this work continued, Frederick Banting had qualified as a 
surgeon from the University of Toronto in 1917.pancreatic duct ligation. The 
remaining islets could then be studied to see if the internal secretion could be 
obtained and identified. He subsequently approached Professor James Macleod at 
Toronto University in an attempt to start researching this theory. Initially sceptical, 
Macleod relented and suggested he try over the 
summer period with some help from the 
physiology student Charles Best (seen left, with 
F Banting and experimental dog). They 
commenced work in May 1921. During the 
summer of 1921 and into 1922 they continued 
their work, joined later by James Collip a PhD 
biochemist.  By December 30 1921, they 
presented a paper to prominent people in 
diabetes research at the American Physiological 
Society Conference. The paper was entitled: 
‘The Beneficial Influences of Certain Pancreatic Extracts on Pancreatic Diabetes. 
The meeting was not a great success as many flaws in the research were identified. 
This somewhat served to focus the groups’ direction. By improving extraction 
techniques and purification methods they were ready to try the extract on humans, 
and on 23rd January 1922, a young man with diabetes, Leonard Thompson received 
the first injection of this purified extract given to a human. A hypoglycaemic 
response was found and continued on further administration. By May 3rd 1922 the 
group announced that they had isolated the internal secretion of the pancreas and 
they called it insulin. 
Banting, Best and dog. 
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Although a ground-breaking 
announcement, months of 
difficulties followed particularly 
concerned with the problems of 
large scale isolation and 
production. Eli Lilly Company 
stepped in to help, and after some 
difficulties initially, the production of 
insulin in reasonable quantities 
began in August 1922. Initially beef 
insulin was isolated from the 
pancreases of cows and provided a 
decent volume of insulin extract. 
The purity of this extract remained an issue and reactions to injections of it remained 
a problem until purification techniques improved. Pig insulin was also produced and 
used as an alternative to bovine insulin and but as 
before purity issues and reactions to injections were 
also noted.  
In 1936, as the purity of both extract increased, insulin 
was combined with protamine- a protein from river trout 
semen- to delay absorption and produce slow-release 
insulin. The further addition of zinc led to the 
production of the first long acting insulin, Protamine-
Zinc insulin (PZI). In 1950 the production and sale of a long acting insulin named 
Neutral Protamine Hagedorn (NPH) began. It had the advantage of being able to 
form crystals and the ability to be mixed with shorter acting insulin to form a 
combination treatment. 
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Eventually technology and research facilitated the development of human insulin. 
Research during 1963-66 in Germany, China and the United States demonstrated 
human insulin could be synthesised and in 1975 fully synthetic insulin (CGP 12831) 
was produced by Ciba-Geigy laboratories in Basel, Switzerland. Subsequently, 
human analogue insulin was developed by genetic manipulation in 1980 and was 
first tested on 17 volunteers in England. This form now dominates insulin use in 
current clinical practice20-22. During this development the way insulin was delivered 
and various factors affecting the way it was absorbed also influenced current 






20 | P a g e  
 
5.2 Hyperglycaemia and Outcomes. 
5.2.1  Microvascular Disease in T1DM 
By the 1950s patients treated with insulin were noted to develop complications, 
particularly those affecting the kidneys and eyes. Early observational studies in the 
1950s and 1960s associated the prevalence of these complications with the 
presence of high blood or urinary sugar23, 24. The ability to control glucose variations 
improved with the development of shorter and long acting insulin, but also with the 
improved method of measuring blood glucose when compared to urinary glucose 
measurement. 
 In the late 1970s and early 1980s a number of early interventional studies 
examined how attempting to control the blood sugar over and above the goal of 
removing osmotic symptoms would affect the development or progression of 
microvascular disease. Studies such as the STENO I and STENO II studies 
demonstrated the benefit of good blood glucose control in the development of 
microvascular complications25, 26. 
It took the Diabetes Control and Complications Trial (DCCT)1 interventional study to 
definitively demonstrate the benefits of good glucose control in a population of 
patients with T1DM compared to a group of patients who received, what was then 
termed ‘standard-care’. Subsequent to the publication of the DCCT the ‘standard’ 
management of patients with T1DM shifted more towards tighter blood glucose 
control with the aim of reducing microvascular complications. 
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5.2.2 Macrovascular Disease in T1DM.  
Patients with T1DM also suffer significant macrovascular disease. This had been 
recognised as a complication associated with T2DM for many years. 
Hyperglycaemia was thought to be a contributing factor but even well controlled 
patients with T1DM had an excess of macrovascular disease compared to the non-
diabetic population. 
Traditional risk factors for IHD, CVD and PVD, such as smoking, hypertension and 
hyperlipidaemia have all been studied in patients with T1DM and the effects over 
and above good glucose control noted. The management of patients with diabetes 
has more recently moved towards addressing these risk factors as well as 
controlling blood glucose. The evidence for intervening in patients with T1DM who 
have elevated blood pressure and cholesterol is variable. There is strong evidence 
that links poor diabetes control with diabetic nephropathy and patients with 
nephropathy have also been shown to hypertension more frequently than those 
without nephropathy. Whether the existence of hypertension predates the 
development of nephropathy is unclear, but the observation of their co-existence is 
associated with an increased risk of death from macrovascular disease (IHD/CVD) 
and progression to end-stage renal failure. Consequently, newer consensus 
guidelines have included the aggressive management of hypertension in patients 
with evidence of diabetic nephropathy27-29. 
The evidence for managing dyslipidaemia in patients with T1DM is not clear cut. In 
patients with T2DM there is good evidence for the existence of a specific 
dyslipidaemia associated with an elevated low-density lipoprotein cholesterol (LDL-
C) which is small, dense and athrogenic. Treatment with lipid lowering drugs in 
these patients is undoubtedly beneficial30,improving cardiovascular risk and overall 
mortality.  In patients with T1DM this dyslipidaemia is less frequently found. Often a 
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normal a near normal profile predominates or hypertriglycerideamia is seen. 
Improvement of glycaemic control often corrects this31. 
The cardiovascular benefits of lowering lipids in T2DM, has however, led to a trend 
towards aggressive lipid management in patients with T1DM. There is evidence of 
benefit in addressing cardiovascular risk factors in patients with T1DM and 
nephropathy32. However the benefit of cholesterol management in patients with 
T1DM but without nephropathy is less clear33. The most recent guidelines 
recommend lipid-lowering therapy only in those patients with persistent poor control, 
long duration of diabetes or the co-existence of other risk factors34. 
More recent evidence has shown that intensive diabetes control – as used in the 
DCCT trial – has long term beneficial effects on surrogate markers of35, as well as 
on the actual risk of cardiovascular disease in patients with T1DM36. These effects 
appear as the duration of diabetes increases, although there appears to be an 
independent association with the degree of glycaemia11. These issues are 
discussed further in the literature review.  
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5.3 Technologies, Insulin and drugs. 
5.3.1 Delivery Technologies 
The improvements in diabetes care have often been mirrored by improvements in 
the medications such the development of human then analogue insulins and 
technologies used to manage diabetes.  
Insulin Injection devices 
Initially insulin was administered via a glass syringe and a standard metal needle. 
The first commercially available glass syringe was made by Becton, Dickinson and 
Company in 1924. Insulin injection was time-consuming and had numerous 
problems associated with it such as repeated use and sterilisation of insulin injection 
equipment and needles.  By 1952 the first sterile disposable syringes were 
available. Accompanying this was the development of smaller, thinner and 
consequently less painful needles for injection. By 1969 the first disposable self-
contained syringe and needle was available. The development in 1985 of the first 
‘pen-device’ and pen needle for administering insulin was a major step forward. The 
Novopen was launched by Novo Nordisk37 but was quickly followed by pen devices 
made by other manufacturers. Pens have quickly established themselves as a 
popular method of insulin delivery where they are available, they are clearly 
convenient and patients report satisfaction and improved quality of life with their 
use38-40. 
Insulin pump devices 
The development of the continuous subcutaneous insulin pump has also provided 
patients with an alternative source of insulin delivery. Initially, when pumps were 
developed in the 1960s, they were cumbersome and prone to failure. Over the years 
the technology progressed to with pumps becoming increasingly miniaturised.   
Current models are hardly bigger than a credit-card (Fig 5.3.1). 
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Fig 5.3.1 Comparison of older and new blood glucose meters 
In selected T1DM patient groups improvements in quality of life are documented41. It 
is clear however, that pump technology is not suitable for use by all patients42-44. 
These pumps are external devices; however implantable pump devices were also 
developed. Whilst external pumps use the subcutaneous delivery method, 
implantable pumps deliver insulin into the peritoneal cavity, which offer the promise 
of a more physiological insulin delivery, it being absorbed directly into the portal 
system. The initial implantable pumps were designed and made in the 1970s, for 
example the Infusaid pump45; more sophisticated pumps following in the 1980s. 
However by the 1990s only one pump was being manufactured – the MiniMed 
Implantable Pump46. The necessity of having to undergo a surgical procedure for 
implantation was always an issue with these pumps, as well as other associated 
problems of use. They have not made the transition into routine clinical use but are 
still used in research settings or part of specially selected centres. 
 
 
Old and newer insulin pump devices 
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Alternate delivery devices and routes 
Further alternative insulin delivery methods have also been developed. An inhaled 
insulin device was launched in September 2006 but its uptake and use by clinicians 
was low and the reasons for this have been discussed in the literature47-49 major 
influences were the lack of long-term safety data, the unknown long-term effects of 
insulin on lung function and the cautious nature of many practicing clinicians. The 
National Institute of Clinical Excellence (NICE) also advised limitations on its’ use50 
and in April 2007 it was subsequently withdrawn from sale in the UK, although 
support exists for those still using it. The use of inhaled insulin may reappear at a 
later date as the licence for the technology used to create and deliver this form of 
insulin has been taken over by another company. Other methods of insulin delivery 
such as buccal51, intranasal52 and oral insulin53 have also been examined, however 
their success at providing insulin at doses to be effective in clinical practice has 
been poor. 
 
5.3.2 Monitoring Technologies 
Urine testing 
Methods to detect glucose in urine preceded the use of insulin by many years. For 
example, Francis Home detected glucose in urine by fermentation demonstration in 
178054. Once blood glucose concentration exceeds the renal threshold for disposal 
of glucose, approximately 11 mmol/l, then it appears in the urine and is detectable. 
As with other investigations, urine testing has subsequently developed into 
sophisticated multi-test urinalysis which allows detection of glucose, ketones and 
other products in the urine. Initial testing was much more problematic though, 
Benedict’s solution was in common use in the 1930s and 1940s and required the 
tester to boil the reagents for five minutes to detect glycosuria55, 56. These issues 
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were resolved as technology developed, Bayer Laboratories producing effervescent 
tablets (Clinitest, 1941) which simplified this reaction to a more practical user-
friendly test. Subsequently dip and read clinical test strips (Clinistix, 1956) were 
developed for the detection of glucose in urine. This test used the process of 
enzymatic breakdown of sugar followed by an oxidation reaction. The oxidation 
causes a colour change which is proportional to the sugar content of the urine. This 
colour is then compared to a visual read strip. The convenience of these tests led to 
their widespread use57. By the 1960s Bayer had developed a test strip for detecting 
and quantifying the amount of glucose in blood (Dextrostix) using the same method 
described above. 
The measurement of proteins in the urine, initially albumin and subsequently 
microalbumin followed a similar course of development. Originally albumin in the 
urine was detected by heating and observation. Richard Bright commented on 
“albuminous nature of urine” in his to description of the clinical symptoms of 
nephritis in 1827 in “Reports of Medical Cases”58. In the following years test strips 
were developed to detect protein in the urine. Subsequently clinical studies 
demonstrated it was a good predictor of worsening renal disease. However tests 
which identified the presence of protein in the urine in ‘micro’ amounts, allowed 
earlier intervention to occur.  The subsequent tests for ‘micro’-albuminuria followed: 
radial immunodiffusion, immunoelectrophoresis, radioimmunoassay, enzyme 
immunoassay, latex-bead immunoagglutination, turbidimetric immunoassay and 
dye-binding59. Such testing is now a part of routine diabetes care, aiding in the early 
identification and management of previously undetectable renal disease.  
Blood testing 
Urinalysis for glucose control has been superseded by accurate methods of 
assessing capillary blood glucose concentrations. This has become a very useful 
27 | P a g e  
 
method of guiding insulin doses and monitoring glucose excursions. Capillary blood 
ketone testing has also demonstrated its value in clinical use60, 61. 
Bayer once again led the way, after developing Dextrostix, they introduced the first 
portable blood glucose meter- known as the Ames Reflectance Meter (ARM, Fig 
5.3.2.1). 
 
Dextrostix were a visual test strip, meaning that after exposure to blood the strip 
would change colour, by a chemical reaction in response to the blood glucose, and 
this would be visually compared to a chart giving a glucose concentration. This 
method was semi-quantative and as such, prone to error. The reflectance meter 
replaced the visual comparison and read the strips directly, the needle deflecting 
along the scale to give a glucose concentration. Although this improved accuracy of 
readings they were still error prone. Subsequent modifications of the ARM by Bayer 
improved its function and accuracy and by the 1980s they were producing the 
Glucometer and Dextrometer. These were then quickly followed by meters produced 
by other companies, such as the Accu-Check meter by Boehringer-Mannheim- 
Fig 5.3.2.1 Ames Reflectance Meter, 1969. 
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which used Chemistrip bG and the Medisense meter by Abbott. The Chemistrip bG 
developed into the most frequently strip used and became known as the BM stick 
after the company which made it. The Medisense meter was a technological 
breakthrough as it was the first electro-chemical based meter and therefore did not 
rely on light reflectance of a colour change to be interpreted by the meter. This 
improved the accuracy of the readings and as a consequence their reliability and 
clinical usefulness62, 63.   
Once it became clear that good glycaemic control was associated with long term 
microvascular outcomes such as retinopathy and nephropathy then home blood 
glucose monitoring became important, and soon moved from a tool used to assess 
glucose variations into an intrinsic part of diabetes management, particularly in 
intensive regimes64-66. 
Continuous glucose monitoring systems (CGMS) 
The development of the continuous glucose monitoring system (CGMS) in the late 
1990s67, 68 allowed the study of glucose variability, via 288 separate measurements 
over a 72 hour window. Initially used in paediatric practice, the CGMS is increasingly 
being used in other patients with type 1 diabetes to help improve control. It is 
particularly useful at helping identify periods of unrecognised hypoglycaemia69, 
notably overnight, but also in tailoring intensive insulin regimes so that wide glucose 
variability is avoided. Such systems are one of the many tools used to optimise 
control for patients with T1DM, although the evidence for improvement in glycaemic 
control is still variable70-72, it does help patients gain a greater understanding of the 
relationship between glucose excursions and insulin use. 
Glycated Haemoglobin  
The analysis of blood proteins, including haemoglobin and the effect of glucose 
upon them has also been studied. This led to the development of the fructosamine73, 
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74
 and haemoglobin A1 tests75, 76. The latter test was modified and standardised to 
the currently used HbA1c (DCCT aligned). This has shown significant correlation 
with long term complications and has become one of the standard tools by which 
insulin therapy is guided77. 
Further standardisation of the HbA1c assay is currently taking place, this will allow 
international comparisons to be more accurate77, that and rigorous comparisons 
between international area maintain these standards78. 
More recently debate has been ongoing within the diabetes profession about the 
use of HbA1c as a monitoring tool in comparison with the a measure known as 
estimated average glucose (eAG)79-81. Both measures have their uses, eAG being a 
more patient centred measure as it relates to self-monitored glucose values. 
However, HbA1c has been definitively shown to correlate with microvascular 
disease and thereafter complications, and so provides a useful tool for 
management. The most popular measure will prevail in due course, although it 
would be reasonable to expect both will be used in clinical practice. 
Such technological advancements have made the monitoring of diabetes easier and 
have allowed improvements in glucose control to occur. This has coincided with 
improved insulins which have enabled more flexibility and adaptability in their use 
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5.3.3 Insulin Technology 
The introduction of insulin into the treatment of T1DM was a medical milestone, 
since that time however it has become apparent that insulin replacement would be 
more effective if it mirrored the normal physiological production of insulin.  
Physiological insulin release in non-diabetic healthy people is a dynamic response 
between the metabolic requirements for fuel and glucose production. In basic terms 
a ‘basal’ level of insulin is secreted in pulses; with a secondary surge in insulin 
production on consumption of a meal. This response ensures adequate disposal of 
new glucose into active metabolic processes e.g. exercise or into storage. Mirroring 
this physiological pattern by injecting deposits of insulin subcutaneously is difficult. 
As technology has progressed attempts have been made to develop insulin which 
would approximate the physiological response. 
Insulins can usefully be divided into the following categories on their putative 
duration of action: 
Rapid-acting:  Insulin lispro, Insulin aspart, and Insulin 
glulisine  
Short-acting:   Regular (soluble) Insulin  
Intermediate-acting:  NPH (isophane) Insulin  
Long-acting:    Insulin glargine and Insulin detemir  
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Table 5.3.3.1 – Time profiles of human and analogue insulin. 
 
This is sometimes displayed as a time-action profile, as seen below (as an idealized 
version). This demonstrates the difference between insulins and the duration of time 
over which they are effective. 
 Insulins have developed considerably since use started in 192282. The analogue 
insulins, as depicted above, which dominate current use, are the end product of this 
development. Earlier insulins are summarised briefly in section 5.1 (pgs 21-22) but 















(Humalog) ¼ - ½ ½- 1 ¼ 3-4 4-6 
Insulin aspart 




¼ - ½ ½ -1 ¼ 3-4 4-6 
Short-acting 
Regular 
(soluble) ½ - 1 2-3 3-6 6-8 
Intermediate-acting 
NPH 





3-4 8-16 18-20 20-24 
Insulin detemir 
(Levemir) 3-4 6-8 14 ~20 





Both bovine (beef) and porcine (pig) insulin were the initial insulins used clinically. 
They were extracted from the pancreata of these animals. Initially these mixtures 
were highly impure, pig insulin contained up to up 8% of porcine proinsulin 
material83, 84 but purity improved as re-crystallisation techniques were used. Gel and 
ion-exchange chromatography also improved the purity85-87.  Such insulin was short 
acting initially and it was not until the combination of insulin with Protamine or zinc 
that longer acting insulins were seen. This occurred in the 1930s and 40s. By the 
1950s other substances were combined with insulin, such as globin, this also 
prolonged the action of these animal insulins88-92. It was also noted that combining 
soluble (short acting) and long acting insulins could be done and in fixed ratios, the 
use of this ‘mixture’ could be clinically useful93. The use of animal insulin either in 
fixed mixtures or free mixing of soluble and isophane insulin continued until the 
1980s when the first ’human’ insulin was produced. 
 
Reprinted with permission from WWW.ENDOTEXT.ORG, the free on-line Endocrinology Web-book, 
Chapter  20, INSULIN PHARMACOLOGY, version 6/15/2009, by Sinan Tanyolac, MD et al. 
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Human Insulin 
Human insulin was initially synthesised in semi-synthetic or biosynthetic forms. 
Semi-synthetic human insulin is made when porcine insulin is converted by the 
substitution of the amino-acid alanine by threonine at chain position B3094. Bio-
synthetic human insulin is derived by one of two methods; enzymatic alteration of an 
intact human proinsulin gene inserted into a non-pathogenic strain of Escherichia 
coli95 or from foreshortened synthetic proinsulin produced by genes which had been 
inserted in yeast96, 97. The clinical transition to such insulin use occurred in the mid 
1980s and it was not without controversy. Frequent reports of increased 
hypoglycaemia were seen98 and although it was thought to be a function of these 
insulins alone, it became apparent that this was not the case99, 100.  The use of these 
insulins still continues today, although in more recent years patients and healthcare 
professionals have often decided to change to the analogue insulins. 
Human Analogue Insulin 
As shown in the table above, there are now three short acting and two longer acting 
human insulin analogues commercially available. The short acting insulins have a 
decreased tendency to hexamer formation and so have a rapid absorption time. 
These analogues have specific amino-acid substitutions which lead to 
conformational and electrical changes within the molecule which decrease this 
hexamerisation101. Insulin Lispro (Humalog, Eli-Lilly) swaps the positions of two 
amino acids, placing lysine at B28 and proline at B29102. Insulin Aspart (Novorapid, 
Novo-Nordisk) replaces the proline at B28 with aspartic acid103, 104. Insulin Glulisine 
(Apidra, Sanofi-Aventis) substitutes lysine at position B3 and glutamate at B29 to 
have its effect105. All of these insulins are comparably faster than human insulin at 
being absorbed subcutaneously and so lend themselves well to the basal-bolus 
regime where rapid prandial insulin useful. 
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The two long acting insulins, Insulin glargine (Lantus, Sanofi-Aventis) and insulin 
detemir (Levemir, Novo-Nordisk) also have amino acid changes, but these differ 
considerably from the short acting insulins. Glargine has a diarginyl moiety added at 
B30 and glycine substituted at A21. This structure results in precipitation of the 
molecule at neutral pH, as found subcutaneously, and consequently a slower 
absorption106. Insulin detemir, meanwhile has a C14 fatty acid molecule, myristic 
acid, attached at B29 which consequently delays its absorption, giving it a nearly 24 
hr duration of action as well107.  
In comparison to the previously available insulins, the newer analogue insulins, 
rapid-acting ones having a fast onset and disposal and long-acting insulin having a 
more ‘peakless’ profile, could theoretically allow more aggressive dose titration to 
control blood sugars as the risk of hypoglycaemia would be reduced108. In clinical 
practice there is some evidence that the incidence of hypoglycaemia is lower on 
these newer insulins, although evidence of improved glycaemic control is less easy 
to demonstrate. Quality of life studies would suggest that the newer insulins are 
preferred by most patients20, 109, 110. 
Restoring physiological insulin production- transplantation. 
Whole pancreas and more recently Islet-cell transplantation have been explored as 
a form of permanent treatment for T1DM. Whole pancreas transplantation (WPT) as 
treatment for T1DM was first performed in 1966111. Due to poor graft survival, not 
many procedures were performed before 1978. However, by the year 2000 over 
14000 transplantations had been performed worldwide, the increase in numbers 
being due in part to improved immunosuppressive therapies, improved surgical 
technique and better patient selection112. It is clear that graft survival is better when 
WPT occurs with simultaneous kidney transplantation for end-stage renal failure. 
35 | P a g e  
 
Less success is seen with lone WPT such that The American Diabetes Association 
only recommends this in patients with severe problems, such as  
1) A history of frequent, acute, and severe metabolic complications 
(hypoglycemia, hyperglycaemia, ketoacidosis) requiring medical attention;  
2) Clinical and emotional problems with exogenous insulin therapy which are 
so severe as to be incapacitating;   
3) Consistent failure of insulin-based management to prevent acute 
complications113.  
Islet cell transplantations were first performed in humans in the 1970s114. The 
pancreatic islets are separated by digestion by a collagenase enzyme from 
pancreatic tissue115 and they are then subsequently purified. The islets comprise 
about 1.5% by weight of the whole pancreas116. Further attempts were made in the 
1980s and 90s at Edmonton in Canada, but success was poor with insulin 
independence rarely reported117.  More recently these early failures, probably due to 
poor islet preparation and immunosuppression118, have been improved upon119. Islet 
cells are infused into the portal vein by the placement of a temporary catheter. The 
liver being chosen as the transplant site because it is highly vascular which favours 
graft implantation, and also because insulin would be secreted into the portal 
circulation, as in the non-diabetic individual118.   
Transplantation (WPT and islet) however, remains difficult with recognisable 
complications such as a surgical procedure, wound infection and graft failure for 
WPT implantation. Bleeding and portal vein thrombosis are the most common risks 
in islet transplantation. Both procedures also require the use of immunosuppressive 
therapy to prevent rejection and this can put patients at risk of infection and indeed 
increased incidence of malignancy. Whilst this remains a promising area of research 
and further studies are ongoing, for the majority of patients this is not a practical 
alternative to subcutaneous insulin treatment120-123. 
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5.4 Systems and Patients  
The availability of technology such as sophisticated home blood glucose monitors to 
aid glucose control, the development of insulin analogues and the convenience of 
pen devices and finer needles to deliver insulin have all been major improvements 
toward the goal of improving glycaemic control over the past 10-20 years. Despite 
all these advances, their whole effectiveness depend on the patients with T1DM 
actively and consistently using these technologies to augment their care. Finally, the 
patient needs to be closely involved with their medical management and with a 
chronic disease such as T1DM this involvement and engagement is a lifelong 
commitment. 
 
5.4.1 Systems of Diabetes Care 
The delivery of diabetes care is an increasingly complex issue. When viewed 
globally many different health-care systems exist, but this thesis will concentrate on 
the systems delivering care in the United Kingdom. 
Historically in the UK, most forms of health care are delivered within a tiered 
structure. Patient contact is generally initiated at the General Practitioner (GP). 
Referral, if required, is then made to secondary care services (usually a District 
General Hospital). Tertiary referral to ‘specialist’ centres occurs either directly from 
the GP or more usually from the DGH. 
Over the last 60 years successive changes in Government have resulted in 
alterations of health policy (see table below). The more important changes are 
detailed following the table. 
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Year Events Legislation and Documentation 
2006 
Department of Health - Payment by Results 
National tariff 2006/07 
Strategic Health Authorities reduced from 28 to 10 
PCTs reduced to 151 
Supporting practice-based commissioning in 2006/07 by 
determining weighted capitation shares at practice level 
Our Health, Our Care, Our Say 
Supporting people with long 
term conditions to Self Care 
2005 
Modernisation Agency replaced by NHS Institute for 
Improvement and Innovation. 
Department of Health - Treatment Centres 
Department of Health - Direct Payments 
A Patient-led NHS 
Healthcare reform in England, 
Update and next steps. 
2004 
Patients Forums 
Commission for Healthcare Audit and Inspection 
First wave Foundation Trusts established 




Community Health Councils abolished 
NHS Modernisation Agency 
Regional Directorates of Health and Social Care abolished 
Building on the Best; Choice, 
Responsiveness and Equity in 
the NHS 
Health and Social Care 
(Community Health and 
Standards) Act 
2002 
Abolition of NHS regional offices   
Reorganisation of health authorities, from 96 to 28 strategic 
health authorities in England,  
Patient advisory and liaison services 
Wanless report:  
National Health Service Reform 
and Health Care Professions 
Act 
Delivering the NHS Plan 
2000 
Abolition of the NHS Executive  
Primary Care Trusts (first wave) - eventually to reach 300 
National Service Frameworks 
The NHS Plan 
1999 
Primary Care Groups (481) 
National Institute for Clinical Excellence 
Commission for Health Improvement 
Walk-in NHS Centres 
Health Act 
Saving Lives: Our Healthier 
Nation 
1998 Abolition of GP fundholding A First Class Service: Quality in the New NHS 
Table  5.4.1 : Summary of key changes occurring in National  Health Service (NHS) organisation 
since 1948. 
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• General Practitioners were permitted to become fundholders in 1989; 
allowing them to purchase services, such as diabetes management, from 
any provider of that service.  
• Subsequently, this policy was modified when fund holding was taken back to 
the Strategic Health Authority and Primary Care Trusts developed (2000). 
Also hospitals providing care became independent trusts i.e. not financially 
managed by the strategic health authority124. 
• Further changes in health policy and the organisation of primary care 
provision occurred in 2004/2005 with the adoption of the General Medical 
Services (GMS) contract.  
1996 
Community Fundholding  
Reorganization of regional health authorities to reduce 
numbers from 14 to 8 regions. 
Health Service Commissioners 
(Amendment) Act 
Community Care (Direct 
Payments) Act 
1991 
Establishment of 57 NHS Trusts  
Reconfiguration of district health authorities as health 
authorities 
GP Fundholding - 306 practices 
Purchaser/provider split 
Junior Doctors, the New Deal. 
Working Arrangements for 
Hospital Doctors and Dentists in 
Training 
1988 Department of Health and the Department of Social Security split  
Community Health Councils  
 
1986 NHS Management Board established 
 
1984 General Managers appointed throughout the NHS   
1974 
Establishment of Regional Health Authorities and Area 
Health Authorities 
Community Health Councils 
"Management arrangements for 
the reorganised NHS" 
Democracy in the NHS 
1949 Introduction of prescription charges National Health Service (Amendment) Act 
1948 5 July The appointed day- Beginning of the National Health Service 
Children Act 
National Assistance Act 
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Many chronic diseases were structured under the Quality outcomes Framework 
(QoF) and diabetes care was included. Under this system primary care physicians 
have their income partially linked to achieving a series of outcome measures. With 
respect to diabetes care, factors such as HbA1c, Blood pressure, and screening of 
urine microalbumin-creatinine ratios were included. When the percentage of patients 
achieving the target values within a practice increased, so did the income. Clearly 
this performance –linked income could be used to drive improvements in the ‘care’ 
delivered125.  
Whether such moves have had an effect on clinical outcomes i.e. microvascular 
complications is unclear. There has however been a significant impact on the 
delivery of diabetes care as a result of these changes126, 127.  
For patients with T1DM early referral to secondary care services generally occurs, 
although some patients may have already presented, usually through metabolic 
decompensation, to hospital and will continue with this follow-up. Secondary care 
services usually supervise care and manage the patient as an outpatient, liaising 
with the GP. The nature of diabetes care has resulted in a ‘team’ of multi-disciplinary 
health-professionals developing within the diabetes speciality and delivering care in 
the form of a ‘Diabetes-Team’ 128. Such teams generally include a Physician, 
Diabetes nurse specialist/educator, podiatrist and a dietician. A shared-care policy 
with the GP allows regular review of medication and management from both primary 
and secondary care129.  
In an effort to provide a similar standard of care nationally the government issued a 
National Service Framework (NSF) for Diabetes care in 2001. This aims to provide a 
series of agreed national standards of provision and delivery of care and eliminate 
any inequalities of care between areas130, 131. 
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These changes have resulted in specialist diabetes teams adapting the services 
provided in an effort to evolve with the system. Some care teams now straddle the 
once clear delineation between community and secondary care by providing 
‘Community Diabetes Consultants’ to provide education and training to primary care 
teams, oversee and develop referral pathways and to facilitate rapid referral to the 
specialist teams. Other teams have adapted by fine-tuning the services they provide 
to patients with diabetes, making referral pathways more structured and direct. 
Which model of care will prevail over the next few years is uncertain, but such 
changes do provide an exciting challenge for those teams aiming to provide 
excellent care for their patients with diabetes. 
 
5.4.2 Patients with type 1 diabetes 
Where does the patient with type 1 diabetes fit in with the changes seen in health 
policy, care-providers, technological developments and newer insulins? To simply 
provide a patient with insulin or other medication to treat their diabetes does not 
mean that their disease has been addressed. The care that is offered to patients has 
to be contextualised to take into account multiple factors. The American Diabetes 
Association (ADA) recommends that HbA1c targets are individualised132, 133. Indeed 
it may be appropriate to try and make all care targets individualised. What any one 
patient will understand in an education programme may not be understood by 
another, whilst one patient’s love of exercise may be the complete opposite of the 
sedentary or physically restricted patient. 
In essence, as with all branches of medicine, a ‘package of care’ is not necessarily a 
one-size-fits-all solution for all patients. Diabetes teams have attempted to address 
such issues with a variety of different approaches to involve and engage the patient 
in their own care. Educational packages have developed to suit those who learn 
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more effectively in one-on-one sessions, as well as those who appreciate the value 
of peer group support. Specialist nurse care and physician outpatient contacts have 
evolved in an attempt to offer individual treatment and set individual goals. Part of 
this care is reliant on the therapeutic relationship and trust established over 
consecutive visits. 
It is difficult to study the way a patient manages their diabetes in the ‘real-world’ as 
opposed to studying a patient in a time and goal defined clinical trial, particularly 
when you consider the myriad of factors which can impinge on their lives. In this 
thesis I have attempted to address some of the issues that patients face in the real 
world when managing their disease and how this can influence the outcome of their 
care. 
I have examined some of these issues using data obtained from a secondary care 
outpatient diabetes clinic for adults with T1DM, who have had continued contact with 
the same consultant diabetologist and diabetes specialist nurse over the period of 
their care. The data has been compared with those patients in the landmark clinical 
trial for T1DM, the DCCT, to assess whether a real-world group of patients can 
achieve similar results. 
The clinical follow-up of this patient cohort has spanned many of the changes 
discussed in this introduction. I have therefore re-examined their care in the light of 
some of the more recent changes and attempted to assess the impact of them on 
measurable outcomes.  Some of the challenges of inpatient diabetes care are also 
discussed. This is an increasing area of interest in diabetes care, the evidence 
suggesting that the percentage of hospital in-patients with diabetes is rising and that 
the care of these patients could be improved134-138.   
Finally, the complex nature of factors external to diabetes and how they affect T1DM 
is examined in patients with both T1DM and problems with intravenous drug abuse. 
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This appears to be an increasing problem, not just intravenous drug use, but 
recreational drug use as a whole- within the general population and young adults 
predominate. Young adults with T1DM are therefore as likely to use recreational 
drugs as the non-diabetic population. Recent studies have further high-lighted this 
issue139-142.Demonstrating issues with overall control, but also the incidence and 
prevalence of metabolic decompensation. This can clearly impact on general 
diabetes care and control, particularly with young adults, and so this issue is 
described within the thesis.  
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6. Literature review 
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This thesis examines the importance of and challenges to achieving good glycaemic 
control in a population of patients with type 1 diabetes. It also studies the prevalence 
of cardiovascular risk factors and the achievement of management targets in the 
same population, as well as appraising the factors, which in the ‘real-world’ limit the 
ability to achieve these goals. A review of the literature concerning these issues is 
therefore important. 
Diabetes Control and Clinical Outcomes 
The Diabetes Control and Complications Trial1  
 
Modern diabetes care attempts to achieve a normal lifespan free from complications 
for patients with this disease. The landmark trial, the DCCT, set the precedent in 
T1DM demonstrating that glycaemic control was associated with microvascular 
disease outcomes. 
In a randomised control trial of 1441 patients aged 13-39 years of age recruited 
between 1983 -1989 (see Table 6.1 for detail) half the patients received intensive 
therapy and half standard therapy. Each treatment arm was subdivided into two 
groups, a primary prevention half (no evidence of retinopathy or microalbuminuria at 
enrolment) and the secondary intervention half (mild to moderate retinopathy and/or 
microalbuminuria, but not macroalbuminuria). 
Those receiving intensive treatment; 4 injections a day or continuous subcutaneous 
insulin (CSII) and a minimum of 4 self monitoring blood glucose tests a day as well 
as aiming for an HbA1c <6.05%, had better outcomes than those on the standard 
therapy of 2 injections a day and self monitoring by urine glucose tests. 
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Table 6.1 Baseline characteristics of patients enrolled in DCCT 
After almost 7 years of follow-up the average HbA1c was 7.3% in the intensive arm 
and 9.1% in the standard arm. 99% of the patients completed the study (11 deaths, 
32 deemed inactive status (patients who withdrew or were deemed unfit to continue 
the study by a physician), including 8 lost to follow-up).  
Main findings 
For those patients on intensive treatment compared to conventional treatment: 
• 76% reduction in appearance of new retinopathy (1o prevention) 
• 54% reduction in progression of retinopathy (2o intervention) 
• 34% reduction in development of microalbuminuria (1o prevention) 
• 43% reduction in microalbuminuria and 56% reduction in macroalbuminuria 
(2o intervention) 
• 69% reduction in appearance of neuropathy at 5yrs (1o prevention) 
• 57%  reduction in appearance of neuropathy at 5yrs (2o intervention) 
Baseline data of patients enrolled in DCCT 













2.6 ± 1.4 2.6 ± 1.4 8.6 ± 3.7 8.9 ± 3.8 
HbA1c % 8.8 ± 1.7 8.8 ± 1.6 8.9 ± 1.5 9.0 ± 1.5 
Men % 54 49 54 53 
Smokers % 17 19 19 18 
46 | P a g e  
 
Many of the principles behind this study arose out of the groundwork laid in earlier 
studies in patients with T1DM including, the STENO study25, 143 , and the KROC 
collaborative study group144, 145 the findings of which demonstrated that improved 
glycaemic control might have an impact on the development of microvascular 
disease. However, the DCCT proved this definitively with large numbers of patients. 
It is important to recognise though, that the patients recruited to this trial were not 
wholly typical of the general population with T1DM. This group were a highly 
motivated selection of volunteers who had an interest in self-care. Patients with 
other diseases were excluded. The rate of smoking in this group did not perhaps 
reflect that of the general population146. The mean age of the all the patients was 27 
years, whilst the mean duration of diabetes was short in the primary prevention arm 
(2.6 ±1.4 years) and quite short in the secondary intervention arm (8.9±1.5 years). 
Additionally, the patients on the intensive arm of the study received a great deal of 
input to help them achieve their targets, including weekly specialist nurse input and 
monthly physician review. In summary the comparison between these patients and 
those in the ‘real-world’ is not ideal. 
The Epidemiology of Diabetes Interventions and Complications trial147  
 
 
Subsequent to the completion of the DCCT, the majority of the patients in the study 
continued to be followed up in the EDIC147 (Epidemiology of Diabetes Interventions 
and Complications) study, 1425 patients from DCCT were invited, 1375 (96%) 




Total EDIC Patients recruited 
1375 
Previous intensive treatment 
687 
Previous conventional treatment 
688 
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In this study the patients, after discussion with their care providers, adopted the 
most suitable insulin regime for them. They were however, encouraged to adopt the 
intensive treatment regime used in the DCCT. Within 2 years 69% of the previous 
standard treatment group were using the intensive regime or CSII therapy, while 
95% of the former intensive arm patients continued with the same treatment147. By 4 
years of follow-up the average HbA1c of the two former patient groups were no 
longer significantly different and averaged around 8%. However, the previous 
intensive group patients still had significantly lower levels of retinopathy and 
nephropathy than the former standard therapy patients. The prevalence of 
hypertension, closely linked to nephropathy, was the same in the two groups at the 
end of DCCT, but by 6 years into EDIC it was significantly higher in the patients 
previously on standard therapy. The benefits gained from a period of intensive 
glycaemic control seem to persist for years after and are demonstrated well in this 
group of patients followed up in EDIC148. Compelling evidence for the benefits of 
intensive glycaemic control such as this would support its’ adoption into routine 
clinical practice. 
Intensive Diabetes Treatment and Cardiovascular Disease in Patients with Type 1 
Diabetes36 
As both DCCT and EDIC demonstrated the benefits of intensive insulin therapy and 
good glycaemic control in preventing microvascular disease, it was thought a similar 
effect would be seen in the prevention of cardiovascular disease. Unfortunately, 
both studies initially failed to demonstrate such a benefit, although a trend towards 
improvement was suggested. This was attributed to the age of the patients and the 
duration of disease during these studies. Therefore the same DCCT/EDIC cohort 
was reviewed again in 2005 to examine whether any effect on the incidence of 
cardiovascular disease could be seen, and if good glycaemic control influenced this. 
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Of the 1441 patients originally recruited to DCCT, 93% (1341 pts) were followed 
until February 2005. Cardiovascular disease was defined as non-fatal myocardial 
infarction, stroke, death from cardiovascular disease, confirmed angina and/or the 
need for coronary-artery revascularisation. At the time of re-review the mean 
duration of follow-up was 17 years. The mean duration of diabetes was 28 years. 
During this time 46 cardiovascular disease events occurred in 31 patients from the 
former intensively controlled group, compared to 98 events in 52 patients from the 
conventional control group. 
On analysis, intensive treatment reduced the risk of any cardiovascular event by 
42% (p=0.02) and the risk of non-fatal myocardial infarction, stroke or death from 
cardiovascular disease by 57% (p=0.02). 
The decrease in HbA1c that occurred during the DCCT was significantly associated 
with most of the positive effects of intensive treatment on the risk of cardiovascular 
disease. Meanwhile the presence of microalbuminuria and albuminuria were 
associated with a significantly increased risk of cardiovascular disease. The 
differences between the two groups remained even after adjusting for these factors. 
This study was important as it demonstrated something that, although suspected 
had not been fully proven in other trials. Cardiovascular disease is not specific to 
T1DM, but patients with the disease do show rates 10 fold that of an age matched 
population without diabetes. It also demonstrated that the traditional risk factors 
(Smoking, higher body-mass index, higher total and LDL cholesterol) were all 
associated with the development of cardiovascular disease, adding further weight to 
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Limiting Factors to achieving good Diabetes Control. 
These two studies demonstrate the benefits of intensive diabetes control in the 
prevention of microvascular disease. The latter study (EDIC) also shows that without 
the previous high levels of support seen in the DCCT even a trial population struggle 
to maintain glycaemic control close to the DCCT targets. Equally, it also shows that 
patients who were less well controlled can improve their control with physician 
advice and a more intensive insulin regime. The challenge to health professionals 
and patients is to achieve good glycaemic control with limited time and resources 
whilst facing other factors in a non-clinical trial world, which affect how a patient with 
diabetes manages their condition.  
Translating the DCCT into clinical practice; overcoming the barriers149  
 
 
The adoption of the principle of tight glycaemic control into everyday practice is not 
without difficulty; as described in this paper149. It discusses the potential barriers to 
success and identifies the following areas where such difficulty may occur.   
Barriers within the therapeutic regimen to achieving good diabetic control. 
Frequent capillary blood glucose monitoring  
Need to monitor carbohydrate intake.  
 
The Barriers within the healthcare team to achieving good diabetic control.  
The need for a unified message 
Open and ongoing communication with the patient 
 
The Barriers within the patient to achieving good diabetic control.  
Include motivation  
Personal and professional support  
The risk of hypoglycaemia.  
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Addressing these issues in clinical practice, even shortly after the publication of the 
DCCT was an important aspect of diabetes care that many teams appreciated. 
Hypoglycaemia and weight gain were identified as two of the more obvious factors 
which may limit the ability of both the patient and the care team to achieve good 
glycaemic control. 
 
Hypoglycaemia, Insulin use and weight gain. 
Hypoglycaemia in the Diabetes Control and Complications Trial150  
 
This paper, published in 1997, described the problems of intensive insulin regimes 
within the trial; 65% of the intensive control group having had at least one severe 
episode of hypoglycaemia compared to only 35% of the conventional control group. 
This gave a relative risk of 3.28 of severe hypoglycaemia with intensive control. 
Males and those with previous episodes of hypoglycaemia were at particularly high 
risk. Within both groups patients who had experienced severe hypoglycaemia were 
at increased risk of subsequent episodes.  
Hypoglycaemia is a much feared complication of insulin use by the patient and is 
well described by McCrimmon and Fryer151 
Hypoglycaemia has also been associated with an increased dietary intake in the 
hours following such an event. The dietary choices also appear to be poor, 
predominantly consisting of fat and carbohydrate heavy foodstuffs152. It is not 
unreasonable to suggest that intensive insulin regimes, using higher doses of 
insulin, can lead to weight gain through simple insulin use, but also secondary to 
increased hypoglycaemia and subsequent calorie laden food choices thereafter. 
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Influence of Intensive Diabetes Treatment on Body Weight and Composition of 
Adults With Type 1 Diabetes in the Diabetes Control and Complications Trial 153  
This review of the DCCT patients demonstrates that weight gain is a recognised 
complication of intensive therapy. A weight gain of an average of 4.75kg in the 
intensive arm compared to the conventional arm is a factor that both clinicians and 
patients are aware of. 
Patients, particularly young female patients, can be very conscious of weight gain 
and may subsequently indulge in behaviours to avoid it. Eating disorders have been 
reported to be more prominent in young female patients with T1DM than in the 
general population154, 155, although some studies fail to demonstrate this finding 
consistently156. It is clear however, that there is an element of disordered eating 
amongst many individuals with T1DM157-159. The reasons for this are not entirely 
clear, but weight control is a factor to consider in these people, particularly with 
regards to insulin use- or more correctly, under-use. Relative omission of insulin not 
only restricts weight gain but also results in sub-optimal glycaemic control.  
 
Non-compliance and non-attendance; their potential causes. 
DARTS/MEMO collaboration Adherence to insulin treatment, glycaemic control and 
ketoacidosis in insulin dependent diabetes mellitus160  
This study highlighted the fact that 28% of the patients (n=89) reviewed did not take 
the prescribed insulin dose. Those who omitted insulin were shown to have poorer 
glycaemic control and more admissions to hospital with ketoacidosis. These patients 
were young adults with a mean age of 16 and although it is difficult to identify 
formally such behaviours in older groups, it is possible they occur. It is also not 
unexpected to find people who omit insulin and have sub-optimal glycaemic control 
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are less likely to attend outpatient clinic appointments, than those more motivated to 
do so. 
Lost to follow-up: the Problem of Defaulters from Diabetes Clinics161  
This paper reviews the research regarding defaulters from the diabetes clinics. It is 
estimated that between 4-18% of patients default from English hospital clinics 
although this can range up to 40% in some clinics. Various factors have been 
identified to be associated with non-attendance. They are usefully classified as in 
the table 6.1.  
By identifying some of the factors associated with clinic non-attendance it then 
becomes possible to address them and potentially improve clinic attendance rates. 
The paper then goes on to examine some of the methods which could, or indeed 
have been, employed in reducing non-attendance rates, categorising them as 
interventions as shown in table 6.2  
 
Some of these interventions have been adopted in diabetes clinics in an effort to 
reduce non-attendance rates. Encouraging patients to attend clinic is important as 
Patient Socio-
demographic features Patient Clinical Features 
Features of the 
Appointment 
Young Age Doctor Identified psychological problems 
Long intervals to 
appointment 
Male gender Low knowledge about disease Previous non-attendance 
Low socio-economic 
status Health beliefs Time of appointment 
Low educational level  Patient satisfaction with the consultation 
  
Patient satisfaction with 
health professional 
Table 6.1 Classification of reasons for clinic defaulting (taken from Griffin) 
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evidence suggests that non-attendance is associated with adverse patient 
outcomes162,163. Two factors frequently cited as underlying reasons for non-
attendance, as well as being associated with poor outcomes generally, are those of 
socioeconomic status and education. 
Table 6.2 Interventions to improve clinic attendance (from Griffin) 
 
The influence of socio-economic status and educational attainment on 
glycaemic control. 
There have been a number of papers reporting the association between socio-
economic status (SES) and glycaemic control. There remains a problem however in 
how socioeconomic groupings are defined. There is some variation between reports 
from different countries. However, the general interpretation of such data suggests 
that in patients who have lower SES tend towards poorer glycaemic control164-166. 
Not only that, but the prevalence of microvascular disease and the risk of acute 
metabolic complications also appear to be higher164. The association of 
macrovascular disease with SES in these patients with T1DM is less clear-cut 
though, despite higher prevalence rates for smoking and higher cholesterol values 





























register and recall 
systems 
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The role of socioeconomic status, depression, quality of life, and glycaemic control 
in type 1 diabetes mellitus.165  
A cohort of 222 patients with T1DM aged 8-17 was studied and the relationship of 
SES of the patients’ parents/guardians and HbA1c, as well as examining other 
psychosocial factors was examined. It demonstrated a 1.5x greater risk of poor 
glycaemic control in those with lower SES than those with a high SES.   
Relationship between glycaemic control, ethnicity and socioeconomic status in 
Hispanic and white non-Hispanic youths with type 1 diabetes mellitus 168  
In a study of 183 patients aged 21 or less with T1DM in New Mexico, compared 
glycaemic control with ethnicity and SES168. The results suggested, that when 
comparing ethnic differences (Hispanic vs White non-Hispanic), a significant 
association with HbA1c could be found, the Hispanic group having a slightly higher 
HbA1c (8.8% v 8.3%, p=0.03). When comparing all the variables using analysis of 
variance however, only SES demonstrated statistical significance. Those patients/ 
families with a lower SES had significantly higher HbA1c than those patients in 
higher SES groups.  
Educational status- that is level of educational attainment- is closely linked with 
SES, and it is this relationship that has made the direct association of either SES or 
education with glycaemic control difficult.  A study was done of 2387 patients with 
T1DM who were part of the EURODIAB-IDDM169 study and it examined the 
relationship between educational attainment and glycaemic control164. Those 
patients with only a primary education had poorer glycaemic control than those who 
had received a college education. The association with unhealthy lifestyles e.g. 
smoking and little exercise was also stronger in the primary education group. 
Socioeconomic status and educational attainment may be factors influencing the 
glycaemic control of patients with T1DM and this may be because both factors are 
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involved in the motivation of such patients to address their health needs. Addressing 
these areas is something which may bring long-term benefit in many aspect of a 
patients’ health, including glycaemic control, but the remit for this is on a political or 
even a public health platform and not necessarily during an outpatient consultation. 
The factors which can be influenced are often those that both the doctor and the 
patient perceive to be the major obstacles to good glycaemic control and are 
commonly those mentioned earlier such as hypoglycaemia, weight gain and dietary 
management. Many of the developments within the diabetes speciality such as 
analogue insulins, continuous glucose monitoring, carbohydrate counting and 
DAFNE courses for example, have focussed on addressing these areas. 
 
Insulin formulations and glycaemic control 
Long acting (basal) insulin 
Insulin use is associated with a risk of hypoglycaemia. This risk is higher with 
intensive insulin regimes. To address this, newer insulins have been developed with 
reputedly more predictable time action profiles, for example Glargine, and 
Detemir106, 170. Theoretically these insulins can be more intensively titrated without 
an increasing risk of hypoglycaemia, therefore allowing better glycaemic control. 
Certainly, with regards to insulin Glargine, clinical trials have demonstrated both a 
lowering of HbA1c and less frequent hypoglycaemia171-173 and although direct 
clinical experience does not fully reinforce the trial data, less hypoglycaemia is 
certainly seen in the real world than with the use of NPH insulin174, 175. Insulin 
Detemir, marketed after Glargine, also claimed similar properties with reduced 
hypoglycaemia compared to NPH insulin171 but with the added benefit of not causing 
significant weight gain. The clinical evidence for this is smaller than with glargine in 
patients with T1DM176,177. Detemir with its shorter half-life has been used twice daily 
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and has been shown to be effective, although use of once daily dosing also appears 
to be as effective178. The weight neutrality of its use does lend it an advantage and 
various theories have been raised as to why this occurs in comparison to other 
insulins. The main theories suggest that as Detemir preferentially binds with albumin 
in the circulation, it is predominantly associated with an effect on the liver, rather 
than in the periphery, limiting hepatic glucogenesis179. Other work carried out in 
patients with type 2 diabetes, suggests it may also act as an agent in influencing 
satiety because of its ability to cross the blood-brain barrier179, 180 and exert its’ effect 
on the central satiety centres. It therefore remains useful in the clinical setting and 
serves as an option for both doctor and patient in addressing both weight control 
issues and hypoglycaemia.      
Short-acting (mealtime) insulin 
The short acting analogue insulins have also been useful in addressing 
hypoglycaemia and stabilising glucose control around mealtimes in comparison to 
the older short acting insulins. The two most frequently used short acting analogues 
are Insulin Aspart (Novorapid) and Insulin Lispro (Humalog).   
Insulin Lispro (Humalog) 
Insulin Lispro improved post prandial glucose control at the expense of an increase 
in fasting  and-pre prandial levels in comparison with soluble insulin when used as 
part of an intensive regime with NPH insulin used as the basal therapy181.  
Improvements in post prandial glucose variation and HbA1c occurred when using 
Lispro compared with normal human insulin and NPH in a multicentre, 32 week, 
cross-over study109. The rate of hypoglycaemia was also reduced in this group. 
Patients have also report improved quality of life using analogue insulin. In a study 
of 770 patients in an open label trial for 12 weeks, quality of life was assessed 
before and after a change in therapy182. Statistically significant improvements in 
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insulin therapy related quality of life scores were seen, as well as improved HbA1c, 
without an increase in hypoglycaemia. 
 
Insulin Aspart (Novorapid) 
In a multicentre study of 90 patients with T1DM, insulin Aspart reduced excursions 
of glucose outside a predefined range in comparison to soluble human insulin. It 
also significantly reduced post prandial hypo and hyperglycaemia183.  
Improvements in data regarding HbA1c are small at best but data on the quality of 
life with the new insulins are well described. A randomised, multi-national open label 
trial of insulin aspart vs normal insulin for 424 patients on an intensified insulin 
regime has reported184. It compared outcomes in quality of life and treatment 
satisfaction between the two groups (2:1 ratio) over a six month period and 
concluded that under study conditions, aspart improved treatment satisfaction and 
quality of life regarding diet restrictions when compared with human insulin. This 
was mainly reflected by improved satisfaction with increased dietary and leisure time 
flexibility. 
Changing from human insulin to analogue insulin does seem to show benefit in 
terms of tighter glycaemic control and smaller post-prandial variations, as well as 
improved quality of life scores. Similar questions of improvement have been raised 
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Continuous subcutaneous insulin infusion devices (Insulin pumps)  
An intensified insulin regime by multiple dose injection can be effective at controlling 
diabetes but has the disadvantage of requiring multiple daily injections. An 
alternative method of insulin delivery is the insulin pump. Here continuous 
subcutaneous insulin infusion (CSII) is the method of delivery and depends on 
regular monitoring and adjustment of the infusion rates around meals and exercise. 
The pump method has been popular for many years but its use in the UK has been 
lower than its use in other countries185, an estimate putting use in the UK at ~1% of 
patients with T1DM compared to countries such as USA where up to 20% of 
patients with T1DM may use pumps. There have been, particularly in the past, many 
barriers to pump use in UK and they include: 
• Availability of financial resources 
• Suitable trained health-professionals to supervise use   
• Lack of knowledge about the effectiveness of CSII.  
There are also differing opinions about who is suitable for pump use. When 
considering a patient for use of an insulin pump, several factors need to be 
considered. These include cost, lifestyle, technical expertise, differing complications 
encountered between MDI and CSII, achievement of normal glucose concentration 
and diurnal blood glucose variation. The relative merits of MDI and CSII are 














Table 6.3—Advantages and disadvantages of MDI versus CSII.  (from Schade 
DS, Valentine V. To pump or not to pump. Diabetes Care 2002;25:2100-2) 
 
 
The evidence of benefit in favour of CSII or MDI depends a little on which 
parameters are examined. Quality of life measures appear to improve in those 
people who change from MDI to CSII41, 187 although this may be age dependent and 
not all evidence supports this claim188. Improvements in HbA1c are seen with pump 
use but they remain marginal when compared to an optimised MDI regime using 
analogue basal and bolus insulin189.  
There appears to be one clear benefit though in the use of CSII and that is the 
reduction in hypoglycaemia42 which is repeatedly reported. This was more readily 
observed in comparison to regimes not using analogue insulin but still appears to 
remain. What also remains is a risk of developing DKA whilst using CSII, which may 
be higher than those on an MDI regime190 and this must be considered before 
initiating a patient on CSII. However, the treatment does appear to be safe and 
effective in certain groups of patients with T1DM and this has been recognised 
recently with a re-appraisal by the National Institute for  Health and Clinical 
Excellence (NICE) of pump technology use in T1DM191. It would seem that the 
Consideration MDI CSII 
Cost of therapy + ++++ 
Lifestyle flexibility ++ ++ 
Technical expertise + +++ 
Complications of 
therapy + ++ 
Glucose 
normalization +++ ++++ 
Decreased glucose 
variability + +++ 
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flexibility that CSII allows coupled with smaller overall insulin doses and less 
apparent hypoglycaemia, could result in benefits in more patients with T1DM than 
we currently see in the UK.  
The insulin pump may not the way forward for all patients; for those for whom the 
pump is unsuitable, or who opt to stay with injections, then intensive insulin therapy 
in the form of MDI remains the treatment of choice. However, as discussed earlier, 
this regime carries with it the potential problem of weight gain. 
 
Addressing weight gain in patients with T1DM  
Methods of addressing weight gain in people with diabetes include dietary control, 
exercise or medication such as metformin or anti-obesity medication. 
Dietary strategies to aid weight control 
 This area seems to have come full circle in the 85 years since insulin was first used. 
Dietary management was the only way to palliate patients with T1DM prior to the 
discovery of insulin. Clearly such strict regimes as advocated in the 1920s are no 
longer relevant. More recently however, a number of different approaches have 
attempted to guide patients in dietary manipulation to limit glucose excursions and 
the potential for weight gain. 
Dose Adjustment for Normal Eating (DAFNE)   
DAFNE192, is a strategy that was developed to allow dietary freedom whilst using 
intensive insulin treatment in patients with T1DM. The results of this study showed 
no significant increase in weight, despite an increase in insulin injections and total 
daily dose. The group assigned to dose adjustment also showed small but 
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significant improvements in HbA1c at 12 months. Improvements in quality of life 
between baseline and endpoint were also noted.  
Other suggested dietary strategies include the use of preferential low glycaemic 
index carbohydrates within the standard dietary advice given to patients with 
diabetes. The idea being that post-prandial hyperglycaemia is limited in comparison 
to normal dietary carbohydrates. The experimental evidence for this in T1DM is 
small and suggests only minor improvements in post-prandial glucose changes, with 
no real significant changes in HbA1c compared to the standard dose. In many of 
these studies weight change was not observed193, 194. Theoretically, post-prandial 
glucose surges can lead to increased fat deposition and weight gain, so these were 
disappointing results. 
Exercise strategies to aid weight control 
Physical exercise is a method to help control weight gain in patients. Regular 
exercise in patients with T1DM is recommended in clinical practice guidelines195-200. 
Studies would suggest that in general these recommendations are not met by most 
patients201, but clearly exercise is beneficial in controlling weight and other 
cardiovascular risk factors. In a study of a moderately well controlled group of 20 
patients, it was shown that regular (>135 mins/week for 3 months) endurance-type 
exercise led to a decrease in LDL-C, systolic and diastolic blood pressure, waist-hip 
ratio, total body fat and body weight. Increases in HDL-C and lean body mass were 
also seen202. These changes occurred independently of changes in glycaemic 
control and there was no significant increase in the incidence of hypoglycaemia. 
Another observational study of 141 patients with T1DM showed a positive 
correlation between aerobic capacity and lean body mass and hand-grip strength. 
Aerobic capacity was negatively correlated with duration of diabetes, fat mass and 
BMI. Interestingly, there was also a weakly positive but statistically significant 
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correlation between aerobic capacity and HbA1c203. The authors concluded that this 
higher HbA1c in patients with higher aerobic capacity may be a function of 
permissive hyperglycaemia practiced to prevent hypoglycaemia during or shortly 
after exercise.  
Medication based strategies to aid weight control 
If diet and exercise cannot limit the weight gain associated with insulin use then 
additional medication may be a treatment option. There are propriety weight-loss 
medications available via prescription and these are often used in the treatment of 
obesity and type 2 diabetes. These are currently Orlistat and Sibutramine in the UK.  
The literature on these is extensive and is not particularly relevant to patients with 
T1DM and will not be addressed here. However, other medication is being 
increasingly used in an attempt to restrict insulin associated weight gain, or aid 
weight loss in T1DM. Those of particular interest are Metformin and Pramlintide. 
Metformin 
Metformin, a biguanide which acts to increase glucose uptake in the liver and 
increase peripheral insulin sensitivity, is more commonly used in type 2 diabetes. In 
recent years it has been trialled in patients with T1DM who appear to have a degree 
of insulin resistance, or who are having issues with insulin associated weight gain. 
As early as 1985 metformin was noted to improve insulin sensitivity in patients with 
T1DM204. This resulted in small trials to assess if glycaemic control could also be 
improved205-207. Clinical use of metformin has continued and is further supported by 
more recent data. In an open label trial of 16 patients aged between 18-40yrs, using 
metformin at doses of 500-850mg twice daily, the authors observed improvements 
in insulin sensitivity and total daily insulin dose after 3 months. They then later 
conducted a retrospective analysis of patients who remained on insulin with 
additional metformin for up to 2 years. These patients showed initial improvement in 
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HbA1c- which decreased with duration of therapy, but also increased quality of life 
and decreased BMI208. 
Further studies of prolonged use of additional metformin in T1DM in normal clinical 
practice are needed to give a clearer picture of its’ sustained benefit. 
Pramlintide 
Pramlintide is a synthetic replacement of the beta-cell hormone amylin. Amylin 
secretion, like insulin secretion, is lost as the beta cells are destroyed. Amylin has 
been shown to have gluco-regulatory effects which complement the effects of 
insulin. These include suppression of post-prandial glucagon secretion and delaying 
gastric emptying. Replacing amylin deficiency with the synthetic analogue 
Pramlintide has been show to reproduce these effects. It was therefore felt that if 
pramlintide were added to insulin therapy in patients with T1DM additional benefits 
may be gained.  
In a double blind, placebo controlled, parallel group, multicentre study of 651 
patients with T1DM209.  Subjects were randomised to either placebo or pramlintide 
injections in addition to insulin therapy for 52 weeks. Pramlintide was given as 
60mcg subcutaneous injections either three or four times a day. By the end of the 
study HbA1c had reduced by 0.29% and 0.34% in the 3 and 4 times a day injections 
respectively, compared with 0.04% in the placebo group. This reduction in HbA1c 
occurred without an increase in insulin use. A significant reduction in body weight of 
0.4kg occurred in both study arms, compared to a 0.8kg gain in the placebo arm.  
When these weight changes were examined in more detail, with reference to BMI at 
recruitment, it demonstrated that weight gain was prevented in lean patients, whilst it 
induced weight loss in the obese or overweight patients.  There appears to be an 
effect on weight loss. However some critics have cited the increased rate of nausea 
associated with initial pramlintide use as being a major contributing factor in the 
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observed weight loss. The rate of nausea was approximately twice the rate of the 
placebo group in this study.  
Further studies have subsequently been performed and notably patient satisfaction 
with pramlintide use has been assessed210. During this trial of 29 weeks duration on 
266 patients (130 pramlintide, 136 placebo) treatment satisfaction with pramlintide 
was reported. HbA1c decreased in both arms of the trial with no statistical 
significance between them; however weight fell by a mean value of 1.5kg in the 
pramlintide arm, while placebo treated patients gained a mean of 1.28kg. Other 
studies have shown similar small benefits211. 
Adjunctive treatments and newer insulins, educational input, diet and exercise and 
additionally improving the way the diabetes outpatient service is structured and 
delivered can all potentially improve clinic attendance and glycaemic control, with 
the aim of reducing the microvascular complications of diabetes.  Increasingly 
clinicians have been attempting to address the macrovascular disease seen in 
patients with T1DM. 
 
Macrovascular disease in T1DM 
The traditional risk factors for macrovascular disease (Blood pressure, smoking and 
serum cholesterol) have been addressed aggressively, often attempting to achieve 
the targets recommended by various professional bodies34, 212. Success had been 
variable and has focused mostly on patients with type 2 diabetes201. Care targets for 
patients with T1DM have often followed those set for patients with T2DM. In general 
for the majority of patients care is still below the desired targets. The reasons for this 
are numerous but include many of the issues which affect achievement of glycaemic 
targets and attendance at clinics already highlighted in this literature review.  
Glycaemic control has been clearly associated with microvascular disease and 
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certainly, it has been know that there is an association between HbA1c and 
surrogate markers of macrovascular disease, such as coronary artery calcification, 
or carotid intima thickness, but until recently, hard evidence has not been available 
for a direct relationship with macrovascular disease. 
 
T1DM and Inpatient care  
Most of the care for patients with T1DM is delivered in an outpatient setting, but 
there are still a proportion of patients for which care is delivered as an inpatient. 
These cases are usually due to a metabolic deterioration requiring a short 
admission. Admissions can also be due to clinical issues which occur as a result of 
diabetic complications or medication use. The number of these admissions is clearly 
small in terms of the hospital population with diabetes, as patients with type 2 
diabetes predominate. However, it is increasing213, 214. Patients with diabetes are 
recognised to have a longer length of stay in hospital than people without 
diabetes215, 216.  Without specialist input, in the form of either diabetes specialist 
nurses or a diabetologist, patients continue to have a longer stay and therefore a 
more costly admission. Attendance by the specialist service decreases length of 
stay, reduces expenditure, aids follow-up and facilitates all round care134, 217-220. 
Even the management of the commonest metabolic disturbance resulting in 
admission, diabetic ketoacidosis, is under-managed by non-specialists. The 
introduction of care pathways has standardised care221, 222 and resulted in more 
accurate fluid and potassium replacement for these patients, attendance by 
specialists during the admission also facilitates education on sick day rules.  
Improving care for both hospital inpatients and outpatients with T1DM remains the 
focus of diabetes care teams. Recently, inpatient care has been the subject of a 
major review by three of the leading professional bodies; the American Diabetes 
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Association (ADA) and the American Association of Clinical Endocrinologists 
(AACE) and  Diabetes UK (DUK), who have issued consensus statements regarding 
inpatient glycaemic control2, 223. The chapters that follow in this thesis serve to 
illustrate these areas further and expand our knowledge of the outcomes and follow-
up of a cohort of patients with T1DM. 
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7. Social setting, Clinic and Patients. 
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As discussed in the introduction, much of the care patients with diabetes receive is 
best considered within the social setting they receive it. Primarily, this is because it 
has a bearing on their educational aspirations, their attitude towards chronic disease 
and their risk of other co-existent disease. A socially deprived area is likely to have a 
higher proportion of the population with other risk factors for cardio-vascular disease 
such as smoking, as well as lower educational attainment and lower long term 
health goals. When this is compared to a predominantly socially advantaged area 
where educational and health goals are high and motivation for good quality self-
care is present, then differences are likely to be seen between the two groups. 
The diabetes clinic which our patients attended sits in a unique position within the 
city of Liverpool. Unusually, it is attended by populations from three different Primary 
Care Trusts (PCTs), that is Sefton PCT, Knowsley PCT and Liverpool PCT. An area 
map is given below (Fig 7.1). 
Fig. 7.1    Map showing position of the Walton Diabetes Centre (A)  
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7.1 Sefton PCT 
The area covered by Sefton PCT (North of Liverpool city centre) is shown in the 
diagrams below. 
 
     Denotes the position of Walton Diabetes Clinic 
The population north of Formby primarily attend the Hospital trust based in 
Southport to receive their diabetes care as this is the closest local hospital, although 
some patients do attend the Walton diabetes clinic. The area between Maghull and 
Crosby and towards Bootle, fall under the catchment area of our clinic. The middle 
area, south of Formby running to Crosby-Maghull can choose- as indeed any patient 
can- to attend either hospital.  
This is relevant when viewing the demographic data on these areas.  The area 
surrounding Bootle and running to the edge of the district towards the location of the 
diabetes clinic contain seven electoral wards which fall into the most 25% deprived 
electoral wards in England. As evidenced here in the wards circled above. These 
areas have a significantly lower life expectancy when compared to the most affluent 
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areas (shown in white and light blue) 74.6yrs v 80.6 yrs. In other markers Sefton 
generally performs poorly. Additionally it has significantly worse rates for poor 
quality housing, binge drinking, low levels of healthy eating, deaths from smoking, 
early deaths from cancer, alcohol related hospital stays, drug misuse treatment and 
importantly, significantly more people with diabetes than the average for England as 
a whole224. 
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7.2 Knowsley PCT 
The area covered by Knowsley PCT (East of Liverpool city centre) is illustrated in 
the diagrams below. 
 
 
         Denotes the position of Walton Diabetes Clinic 
 
The area within the PCT from which patients most commonly attend the diabetes 
service where our clinic is based is predominantly, but not exclusively, above the 
dashed line. Below the line the population tends to attend the diabetes service 
based at the hospital just outside Prescot. 
Much as with the previously described PCT, there are differences within Knowsley 
with regards to health. The figure above illustrates the deprived areas within the 
PCT. The darker the colour, the more deprived. Many of the electoral wards fall into 
the 25% most deprived wards in England. Life expectancy is lower than the national 
average in both men (73.6yrs) and women (78.2yrs). 
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Knowsley is also worse than the national averages in the following variables: GCSE 
examination achievements (5 A-C), smoking, binge drinking, healthy eating, deaths 
from smoking, cardiovascular disease and cancer, alcohol related hospital stays, 
drug misuse, tooth decay and the prevalence of diabetes 225. 
  
 
73 | P a g e  
 
7.3 Liverpool PCT 
The last PCT which acts as a feeder of patients to the diabetes centre, in which our 
clinic is based, is Liverpool PCT; the area it covers is shown below. 
 
 
      Denotes the position of Walton Diabetes Clinic   
The dotted line demonstrates the proportion of the PCT that commonly attend our 
diabetes clinic, areas below this line are more likely to attend the hospital based in 
the centre of Liverpool. 
Men can expect to live 73.2 and women 77.9 years in Liverpool, less than both the 
regional and national average and for women, the lowest life expectancy in England. 
Deprivation scores are also high. The coloured figure above shows the degree of 
deprivation, 24 out of 28 electoral wards are in the 25% most deprived wards in 
England. Liverpool PCT, in common with the other PCTs already described scores 
low in a number of variables when compared to the national averages. Such areas 
include: poor quality housing, poor educational achievement, more violent crime, 
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smoking and binge drinking and low levels of healthy eating. Deaths from smoking, 
heart disease, stroke and cancer are also worse than the national average. Alcohol 
related hospital stays and drug misuse are also worse than national comparators. 
Diabetes prevalence is at the national level226.  
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7.4  The Type 1 Diabetes Outpatient Clinic 
A diabetes clinic has been operating at the Walton Hospital site (now part of 
University Hospitals Aintree NHS Foundation Trust) since the 1950s. Previously this 
operated in the form of a large outpatient clinic (100 patients) once a week; with 
other smaller clinic sessions for new patients, urgent referrals, young adults and 
pregnant patients. A review of the service was carried out in 1987. At that time the 
diabetes service was staffed by two Consultant Physicians with an interest in 
diabetes, one senior registrar and two registrars. Occasional help was provided by a 
senior house officer. Two diabetes specialist nurses worked full-time and there was 
help on a sessional basis from district dieticians and the hospital chiropodist. There 
were around 6000 attendances at the clinic annually by about 2400 patients. 
At the service review the future needs of the diabetes service were assessed and 
the possibility of a separate diabetes centre proposed. This resulted in an increase 
in staff, such that new posts were created and filled and a new diabetes centre to 
house the diabetes service and specifically the diabetes clinics agreed227. The 
building was completed in the spring of 1990. It is shown below in 2009. 
 
Fig 7.4.1 Walton Diabetes Centre Outpatient Clinic 
76 | P a g e  
 
The young adult diabetes clinic was set up in 1991. The clinic is contained within the 
purpose built diabetes centre, which allows for nurse assessment and recording of 
physical data. There are separate consultation rooms for patient contact with 
diabetes specialist nurses, doctors and dieticians. 
 
The clinic has been run by the same consultant physician with specialist interest in 
Diabetes and Endocrinology since its inception. It has been supported by the same 
specialist nurse and has the services of a dietician. Initially the clinic took over the 
care of patients, from the main Children’s Hospital. These patients were resident in 
the catchment area and once they reached 16/17 yrs of age their care was moved to 
this adult service. These patients then continued in this clinic. Younger patients from 
the other clinics at this centre also had their care in this clinic, such as those newly 
diagnosed with diabetes whilst an adolescent or young adult. 
 
The clinic was run with the aim of optimising diabetes care to enable good 
glycaemic control with freedom from troublesome hypoglycaemia. All patients were 
encouraged to choose a basal bolus regime of insulin administration, adopt healthy 
lifestyle choices and discouraged from smoking. As the targets for glycaemic control 
altered over the following decade and beyond, care was kept in line with the 
contemporary guidelines. Over latter years cardiovascular management was also a 
prominent aspect of the overall management as blood pressure, cholesterol and 
ACR were targeted. 
 
Patients were given appointments as frequently as the system allowed (no less than 
yearly) and often attended 3-4 times per year. Clinic defaulters were offered further 
appointments, and chronic non-attendees were contacted at home by the specialist 
nurses, often resulting in a home visit. All patients were able to contact the specialist 
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nurses for advice by telephone and were often reviewed in a nurse run clinic if there 
were specific problems. The clinic continues to run with these guiding principles.  
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7.5 The younger adult patients with type 1 diabetes studied 
Demographic and biophysical data had been recorded on the patients attending the 
younger adults T1DM clinic since it began. This data has been collated and forms 
the basis of the patient cohort which has been retrospectively reviewed at intervals 
over a 10-15 year time period. 
Initially the data was examined to identify a group of patients who had been 
attending regularly over a minimum of 5 years. Those who met these criteria had 
their case notes reviewed in detail, allowing all available records of HbA1c, blood 
pressure, total cholesterol, urinary microalbumin/creatinine ratio, weight, BMI, insulin 
type and dosage and other medication to be recorded. Any specific complications 
attributable to diabetes were noted, as were other co-morbidities. This allowed an 
extensive database to be constructed.  
Statistical average values were calculated for each variable over a minimum of five 
years between 1996 and 2001. Some patients had attended regularly for a greater 
time period and their values were averages of this greater time period. The mean 
values for the group as a whole were also calculated. Those patients who changed 
their care to another service, moved area, defaulted from the clinic or died were 
noted so as to allow comment on the shifting nature of the clinic population. Patients 
who first attended the clinic after the end of 1996 were not included in any analyses.  
Subsequent to this, the same patients were reviewed in 2006 (all attendances) and 
the same variables collated. Thus an average for 2006 was generated for each 
patient and the group as a whole. Once again those patients who were no longer 
attending were identified and comment made. The dispersion of the original cohort 
by end of 2006 is detailed in Table 7.5.1. 
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Table 7.5.1 




1996* 386 - - - - 
2001 261 92 11 22 -125 
2006 214 34 8 5 -47 
*Regular attendees at the Walton Diabetes Centre Outpatient Clinic 1991-1996, and 
subsequently followed in other years 
 
It is worthwhile considering the potential similarities or differences between the 
patients who continue to attend and those eventually lost to the clinic. The 
glycaemic control of the different groups is shown in the table below (7.5.2). These 
are average HbA1c results for each group. 
Table 7.5.2 
Group Number in group (n) HbA1c (%) 
Original Cohort 1991-
1996 386 9.19 
Interval ‘Loss’ 125 9.32 
Cohort 2001 261 9.10 
Interval ‘Loss’ 47 9.33 
Cohort 2006 214 8.66 
Total ‘lost patients’ 169 9.32 
 
Those patients who continue to attend the clinic demonstrate a lower HbA1c than 
those who defaulted, died or moved away (further review of these differences is 
made in the following chapter). This may reflect an underlying difference between 
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the two groups, which could somehow explain the differences in HbA1c. However it 
is possible, and also more likely that it shows that those with continued diabetes 
team input and clinic attendance have an improved HbA1c. Whether this is due to 
self-selection by these patients – those interested in self-care continue to attend- or 
that the input they receive when attending effects this improvement is not apparent, 
although both aspects probably contribute. 
The final 214 patients who continued to attend in 2006 were not dissimilar to the 
whole cohort originally recruited in 1991-1996, except of course being older and 
having a longer duration of diabetes. Their average ages at diagnosis of diabetes 
(20.43 years (2006) v 19.08 years (original)) and the proportion of men within the 
groups were both similar (134 (62.6.%) 2006 v 233 (60.3%) original). It is 
reasonable then to suggest that the 214 patients still attending at the end of 2006 




81 | P a g e  
 
8. Glycaemic control in a type 1 diabetes clinic for 
younger adults.  
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8.1 Introduction 
The intensive therapy group of the Diabetes Control and Complications Trial  
(DCCT) demonstrated that tight glycaemic control ( HbA1c <7%) in young adults 
with Type 1 diabetes reduced the incidence of microvascular disease, when 
compared to conventional care  at that time1. The beneficial effects of tight 
glycaemic control in the DCCT on microvascular complications were maintained in 
the long term, despite subsequent deterioration in HbA1c values.228 Since the 
publication of the DCCT, tight glycaemic control with HbA1c <7%, has been one of 
the central aims of diabetes care. 
The intensive therapy arm of the DCCT was, however, expensive in terms of 
frequent clinic contact. Patients were reviewed on a monthly basis by a physician 
and had weekly contact with specialist nursing staff.  Also, the rate of serious 
hypoglycaemia and the mean weight of patients in the ‘intensive therapy’ arm 
increased, something not seen in the ‘conventional therapy’ arm. 
In 1991 a clinic for young adults with type 1 diabetes was established at our 
hospital. Since then it has been staffed by the same specialist diabetes physician 
and diabetes specialist nurse with a dietician also present. Throughout, the main 
aims of the clinic have been optimal glycaemic control without troublesome 
hypoglycaemia and screening for diabetic complications. This study reports the 
glycaemic control achieved in this clinic and searched for factors associated with 
poor control. 
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8.2 Patients and Methods 
 
The young adult type 1 diabetes clinic was based in University Hospital Aintree, 
Liverpool, North-West England. The patients lived mainly in an urban area and 
originated from a wide spectrum of social groups. 
The same diabetes specialist physician and diabetes specialist nurse have staffed 
the clinic during the study period. All patients saw the clinic dietician at least once 
and the great majority had multiple dietetic reviews.  Follow up appointments were 
offered at least twice yearly, the more problematic patients receiving more frequent 
follow-up appointments. Non-attendees were sent further appointments (at least 3) 
and finally a home visit by the specialist nurse to encourage re-attendance and to 
maintain care was made. 
There were 386 Type 1 patients who attended the diabetes clinic in the 6 years 
between 1991 and 1996 and who had more than one recorded attendance. Data 
was obtained and reviewed from the case-notes of the clinic visits of these patients 
up until December 2001. At each attendance, HbA1c (DCCT aligned) was measured 
and total mean values throughout the study for HbA1c were calculated. The insulin 
dose units/kg body weight was recorded at last attendance and compared with data 
from the end of the DCCT 150, 228. Attendance rates at diabetes outpatient 
appointments were calculated (attended/total appointments offered), and hospital 
admissions for ketoacidosis and hypoglycaemia recorded. Admitted smoking habit 
at enrolment was noted and known deaths were also recorded.  
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8.3 Statistical Analyses. 
 
The individual patient data is not available for the DCCT patients. However, chi 
squared test were used to compare prevalence data from the DCCT and Aintree 
patient groups. The mean values for each patient were combined to allow the 
calculation of total means, for the whole cohort. This was done for each variable. 
Data from the Aintree cohort is expressed as mean (±standard deviation). 
Comparison between groups within the Aintree cohort is made by the Mann-Whitney 
U-test, correlation was assessed by Pearson’s correlation coefficient, significance 
taken as p <0.05.  




8.4.1 Demographic data (Table 8.4.1) 
The demographic data from the Aintree cohort are shown compared to those of the 
DCCT cohort. The Aintree cohort contained more male patients (60%) compared to 
the whole DCCT cohort (53%) (p = 0.015 chi squared). The age at first attendance of 
the Aintree clinic patients was similar to the age at which patients were recruited to 
the DCCT (mean age (±SD) Aintree 29±10 vs DCCT 27±7). However, the duration 
of diabetes in the Aintree cohort at recruitment was considerably greater: (9.5yrs 
Aintree vs 2.6yrs (DCCT primary prevention) vs 8.8yrs (DCCT secondary 
prevention). The patients in the primary prevention group of the DCCT were chosen 
specifically because they did not demonstrate any diabetic retinopathy and had 
duration of diabetes between 1 and 5 years. It is clear therefore that the Aintree 
group were closer to the patients in the secondary prevention arm of the DCCT with 
regard to duration of diabetes. 
 
8.4.2 Attendance and Follow-up (Table 8.4.2) 
386 patients attended the Aintree clinic between 1991 and 1996 that had more than 
one recorded attendance. At end of 2001, in the previous 2 years 261(67.6%) had 
attended at least once, 92(23.8%) had defaulted persistently, 11(2.8%) were known 
to have moved away and 22(5.8%) had died. There had been a total of 4014 
attendances during the study.  
The Aintree cohort had a mean follow-up period longer than the patients in the 
DCCT (7.7 vs 6.5yrs).  In the DCCT 99% of patients completed the study and 
attended 95% of their hospital appointments, in contrast, 23.8% of the Aintree cohort 
had persistently failed to attend reviews in the last 2 years. Only 11 (0.7%) of the 
DCCT group died during the study period, compared to 22 (5.8%) of the Aintree 
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cohort (p<0.0001 chi squared). The Aintree patients who died had significantly 
longer duration of diabetes and were older at diagnosis of diabetes compared to 
those who continued to attend the clinic and those who failed to attend in the past 2 
years. The total mean HbA1c levels between these groups did not differ. (Table 
8.4.2).  
The clinic non-attendance rate (defined as the ratio of appointments not attended to 
the total number of appointments offered during the study) was 0.32.There was a 
significant correlation between the non-attendance rate and higher mean HbA1c 
levels (r= 0.14, two tailed p=0.029). 
 
8.4.3 Glycaemic control  
The mean of all the HbA1c measurements over the study period from the 386 
Aintree patients was 9.19%. This was very similar to the conventionally treated 
cohort of the DCCT (mean HbA1c 9.1%). Only 3.6% (14 patients) of the Aintree 
cohort achieved a total mean HbA1c <7% during the study. In comparison the 
DCCT intensive therapy arm achieved a total mean HbA1c of 7.4% throughout the 
study.  
 
8.4.4 Insulin administration and dosage.  
At the last recorded clinic attendance the majority (58%) of the Aintree cohort were 
administering insulin by multiple daily injections (MDI-short acting insulin, human or 
analogue, with meals, three times a day and isophane insulin at bedtime.) There 
was no significant difference in total mean HbA1c (%) between those patients 
administering insulin by MDI compared with those who elected to continue using 
human soluble and isophane insulin mixtures twice daily (9.1±1.2 vs 9.2±1.3; 
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p<0.6). The mean amount of insulin (U/kg/day) at last recorded visit was not 
significantly different (0.75±0.2 MDI vs 0.67±0.17 twice daily insulin; p<0.8). In the 
Aintree patients the mean prescribed dose to all patients, of insulin per kilogram 
body weight at the last recorded patient visit was similar to that at the end of the 
DCCT; mean 0.74 units/kg/day (n=386, Aintree 2001), vs 0.75units/kg/day in the 
(Former DCCT intensive therapy group n= 687) and vs 0.67units/kg/day (Former 
DCCT conventional therapy group, n=688, data from EDIC enrolment228).  
 
8.4.5 Hypoglycaemia  
Severe hypoglycaemia, (requiring hospital admission) occurred in 0.79 per 100 
patient years of follow-up in the Aintree patients, similar to the conventional therapy 
arm of the DCCT (0.77 per 100 patient years). The intensive therapy arm of the 
DCCT had a higher rate of admission, 1.14 per 100 patient-years (p<0.001 vs 
conventional therapy DCCT). Those Aintree patients who had severe 
hypoglycaemia (n=18) had similar total mean HbA1c levels compared to the 368 
patients who did not (9.3±1.4 vs 9.1±1.3; p=0.5).  
 
8.4.6 Diabetic Ketoacidosis (DKA) 
In the Aintree cohort the DKA rate was 2.39 episodes per 100 patient-years. This 
was higher than in the DCCT; 1.8 and 2.0 episodes per 100 patient-years in the 
conventional and intensive therapy groups respectively. The 39 patients from the 
Aintree cohort who had least one admission with DKA had a significantly higher total 
mean HbA1c in comparison to the 347 patients without such an admission (10.1±1.1 
vs 9.0±1.3; p<0.0001).  
 




The patients allocated to the primary prevention arm of the DCCT had no 
retinopathy changes at baseline, whilst those in the secondary prevention arm had 
retinopathy (greater than background) in around 40% of the patients. This 
microvascular complication is the one most commonly recorded (presence or 
absence, background, laser treated or blindness) in the Aintree clinic population, 
although this data was not available for when they first attended the clinic, data was 
recorded by review in 2001.  
The data showing the prevalence of retinopathy at review in 2001, as well as other 
relevant details are shown in the table 8.4.3. In essence, the patients without 
documented retinopathy in 2001 (141pts (37.9%)) had a lower mean HbA1c (8.86% 
v 9.32%) and shorter duration of diabetes (15.49yrs v 21.84 yrs) than those with 
retinopathy (231pts (62.1%). Direct comparison with the patients in the DCCT is not 
possible, due to the way data was recorded for retinopathy in that trial, and the lack 
of comparable data in the Aintree patients. What is similar however is that those 
patients with shorter duration of diabetes and a lower HbA1c demonstrate a lower 
prevalence of retinopathy than the comparator group. This mimics the contrast 
between the intensive v conventional control arms in the DCCT.   The graphs below 
show the prevalence of complications in the Aintree cohort with reference to the 
duration of diabetes (graph 8.4.1). Secondly, a comparison is made between the 
prevalence of complications in those patients in the DCCT primary prevention arm 
and those patients in the Aintree cohort of similar duration of diabetes (graph 8.4.2). 
The same details are shown for the secondary intervention arm also (graph 8.4.3.). 
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8.5 Discussion 
The reductions in HbA1c levels achieved in the intensive therapy arm of the DCCT 
was associated with decreased rates in the appearance and progression of 
microvascular complications in comparison to conventional therapy at that time. 
These differences in complications persisted even though the differences in 
glycaemic control between the two therapy arms narrowed after the trial ended147. 
The benefits of tight glycaemic control in preventing or delaying microvascular 
complications are therefore clear. However can tight glycaemic control be achieved 
in routine clinical practice?  
Our study directly compares the results from a young-adult type 1 diabetes clinic 
with the results achieved in the DCCT. The Aintree clinic, had from the outset, the 
aims of tight glycaemic control, i.e. the lowest HbA1c level possible, by 
encouragement of multiple daily insulin injections (four times daily) and they were 
reviewed by the same specialist doctor and nurse with dietician input. Freedom from 
troublesome hypoglycaemia however, was also a major aim. The results show that, 
over a longer follow-up period than reported in the DCCT, glycaemic control was not 
as tight as the DCCT intensive therapy arm and was similar to the DCCT 
conventional therapy arm.  It is likely that the explanation for this is multifactorial. 
The Aintree patients had longer duration of diabetes and unlike the DCCT patients, 
were not a selected group of highly motivated subjects who had enrolled in a trial. 
The socio-economic status of the two groups will no doubt have differed, although 
the Aintree patients did not have documented social status, it may be inferred from 
the prevalence of smokers within the group. The DCCT patients were, in contrast, 
predominantly white middle-class people who were motivated enough to volunteer 
for a clinical trial.   They also failed to attend one third of their clinic appointments 
and the non-attendance rate was associated with higher HbA1c levels. There was a 
loss of one third of the clinic population over the 11 years studied, from patients 
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moving away, persistently failing to attend or dying. Failure to attend UK diabetes 
clinics by 20-30% of patients have been documented previously 161, 163, 229. The total 
mean HbA1c of the persistent two-year non-attendees, was found to be similar to 
the total mean HbA1c of the patients who continued to attend the clinic. It is likely 
that many of these long-term defaulters had, in fact, moved away and failed to 
inform the clinic.  
Compliance with insulin dosage is another factor influencing HbA1c levels. Although 
the recorded prescribed dose of insulin in the Aintree patients was similar to that 
given in the DCCT groups, it is likely that some Aintree patients did not comply. 
Evidence from Scotland, suggests that up to 28% of young patients may not use 
insulin at the prescribed doses, leading to persistent under-use of insulin and 
chronically poor control160.  
The avoidance of serious hypoglycaemia was an important part of the management 
of the Aintree patients and hospital admissions with hypoglycaemia were fewer than 
in the intensive therapy group of the DCCT. Undoubtedly many Aintree patients 
would have reduced their insulin dose when hypoglycaemic episodes occurred, 
resulting in higher HbA1c levels in some patients151.    
Omission of insulin by patients, for whatever reason, places them at risk of diabetic 
ketoacidosis (DKA). There was no apparent difference in the rates of admission to 
hospital as a result of DKA between the Aintree cohort and the DCCT patients, and 
no differences between the DCCT therapy arms. However, the Aintree patients who 
were admitted with DKA had a significantly higher HbA1c than those not admitted.  
None of the Aintree patients were treated with continuous subcutaneous insulin 
infusions (CSII) in contrast to many patients in the intensive cohort of the DCCT. 
Some studies suggest that use of CSII may confer an advantage over MDI in 
achieving better glycaemic control 43, 230. However there are obvious limitations of 
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small studies using selected volunteer patients. Also, other studies have suggested 
there is no advantage to be gained in terms of glycaemic control by using CSSI 231, 
232
. CSII is more expensive than MDI administration, requires a highly motivated 
patient without psychological problems, and an experienced diabetes team who can 
provide regular and frequent input into the ongoing care of the patient42.  
Recently, further strategies have been introduced to optimise glycaemic control. 
These include an intensive education programme; Dose Adjustment for Normal 
Eating (DAFNE) 192, and newer analogue insulins110, 172, 183, 184, 233-235. DAFNE may 
produce short-term improvements in HbA1c levels but long-term data on sustained 
tight control is lacking. Again, a highly motivated patient willing to commit time and 
comply with advice is needed, along with considerable nurse educator resources.   
The recently introduced long-acting analogue insulin Glargine may be useful in 
improving fasting hyperglycaemia and reduce the incidence of hypoglycaemic 
episodes in patients with type 1 diabetes 181, 183, 233, 234, 236. It is possible the use of 
long acting analogues may encourage the patient to aim for tighter glycaemic control 
without the fear of hypoglycaemia leading to defensive reductions in insulin doses. 
Is the goal of tight glycaemic control, achievable in unselected Type 1 clinic 
patients? The results from the Aintree cohort suggest that the great majority of 
patients will not achieve this, although long-acting analogue insulin and CSII were 
not used. Many barriers to tight glycaemic control exist in the ‘real-world’ that are not 
found in clinical trial settings. Many patients do not comply with regimens long-term, 
commonly fail to attend clinic regularly or move away from the clinic area. 
Appointments cannot be offered as frequently as visits in clinical trials due to 
resource limitations. Despite the somewhat disappointing HbA1c levels achieved in 
this large cohort of young patients, well organised, structured diabetes clinics have a 
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very important role to play in the screening and early treatment of microvascular 
complications.  
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Table 8.4.1. Demographic data from the Aintree clinic and DCCT cohorts of  






1o Prevention 2o Prevention 
 Conventional Intensive Conventional Intensive 
N (% male) 386(60) 378(54) 348(49) 352(54) 363 (53) 
Mean (SD) 
Age (yr) at 
enrolment 





9.5± 8.1 2.6±1.4 2.6± 1.4 8.6± 3.7 8.9± 3.8 
% Smokers 31 17 19 18 19 
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Table 8.4.2. Glycaemic control (HbA1c) data from the Aintree Clinic Cohort up to 
December 2001 (Mean follow up 7.7±3.01 yrs after enrolment) 



















last 2 years 
261 (67.6) 18.6 (9.0) 8.5 (7.1) 9.1 (1.3) 
Persistent 
defaulters in 
last 2 years 
92 (23.8) 19.6 (10.7) 10.4 (8.8) 9.2 (1.5) 
Known moved 
Away 11 (2.8) 14.3 (7.6) 9.9 (9.7) 9.3 (1.5) 
Dead 22 (5.8) 25.0 (11.8)* 16.7 (9.6)* 9.5 (1.5) 
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Table 8.4.3  Detailing the prevalence of retinopathy in the Aintree patients in 2001. 
Variable Aintree Clinic 
 Retinopathy No retinopathy 
Number (%) 240 (62.1%) 146 (37.9%) 
HbA1c (%) 9.32 8.86 
Duration of diabetes 
(years) 21.84 15.49 
Ex smoker 22 (9.16%) 8 (5.48%) 
Current smoker 65 (27.08 %) 44 (31.43%) 
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Graph 8.4.1 Shows the prevalence of documented microvascular complications in 
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Graph  8.4.2 Shows the prevalence of complications in the Aintree cohort with 
duration of diabetes (10-15 years) in comparison to the Primary prevention arm of 
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Graph 8.4.3  Shows the prevalence of complications in the Aintree cohort with 
duration of diabetes (16-20 years) in comparison to the Secondary intervention arm 
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9. Improvements in glycaemic control and cardiovascular 
risk factors in a cohort of patients with type 1 diabetes over a 
5-year period. 
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9.1 Introduction. 
The care of patients with diabetes has changed considerably in the past decade. 
Developments in insulin technology have lead to the increased use of analogue 
insulin, particularly in patients with Type 1 Diabetes (T1DM). Indeed, the delivery of 
insulin has also changed with the development of pen38, 40, and more recently 
inhaled devices- although this has been with varying degrees of success47, 48. There 
has also been change in diabetes education programmes and the integration of this 
with adjustment of both diet and insulin dose192. The use of insulin pumps has 
increased, although in the UK this increase has not been as rapid or large as some 
would hope42.          
In tandem with a more patient centred approach, such changes would hope to 
improve the quality of life of patients as well as decrease the risk of complications of 
diabetes by improving glycaemic control. This had been the aim of diabetes services 
since before the publication of the landmark Diabetes Control and Complications 
Trial1 however its’ findings demonstrated this and served to focus services on the 
importance of glycaemic control in the prevention of complications of diabetes. 
Furthermore, other modifiable cardiovascular risk factors, such as serum cholesterol 
and blood pressure have come under increased scrutiny and led to a series of 
guidelines being published by prominent bodies. This has resulted in ‘target’ values 
being recommended; these targets have become increasingly tight over the last few 
years as evidence accumulates of the benefits of risk factor control.  
In the UK, the publication of the National Service Framework for Diabetes in 2001130 
was both an attempt to standardise diabetes care nationally and ensure its uniform 
delivery. The recommendations applied to both Primary and Secondary care. 
This was followed, more recently, by the developments that have occurred in 
Primary care as a result of the Quality Outcomes Framework (QoF) being instituted 
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in 2005237. This has been followed by a shift in general health policy with the drive 
towards chronic disease management, including diabetes, being predominantly led 
by community and primary care services where appropriate. 
We therefore felt it was appropriate to assess what effect, if any, such changes have 
had on the care of a cohort of patients with T1DM who have been attending the 
same Diabetes outpatient clinic since before and through many of these 
developments.  
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9.2 Methods. 
We had previously assessed a cohort of patients in 2001, who had been attending 
the same diabetes outpatient clinic at an urban hospital in Liverpool, in the North-
West of England. These patients were all known to have Type 1 Diabetes (T1DM). 
They originally began attending the young-adult clinic between 1991 and 1996, and 
during that time had at least two consecutive attendances. They were seen by the 
same Consultant Physician and Diabetes Nurse Specialist. During that time they 
had been managed under the principles of tight glycaemic control but with freedom 
from recurrent hypoglycaemic events. The patients were also encouraged to use a 
flexible insulin regimen in the form of three short-acting and one long-acting insulin 
injection (MDI / Basal-Bolus). The choice to do this, or remain with twice daily pre-
mixed insulin injections, ultimately remained with the patient. They were all seen by 
a dietician at least once. Other healthy lifestyle choices e.g. smoking cessation and 
regular exercise were also reinforced. Management of blood pressure, cholesterol 
and screening and treatment of microalbuminuria was in line with contemporary 
guidelines.  
Due to the evolving nature of diabetes care, the progression in technology and the 
increasingly pro-active treatment of cardiovascular risk factors, we decided to review 
the remaining patients who were attending the same clinic in 2006; assessing what 
change, if any, had occurred in biophysical markers, medications and outcome in 
the intervening five years. 
Originally, in 2001 all previous clinic attendances of all eligible patients were 
reviewed. Biophysical data from each attendance was recorded. Average values for 
each variable of each patient were calculated during their period of follow-up. Data 
for the whole patient group was then presented as an average of these values. In 
early 2007, a review of the clinic attendances during the year ending December 31st 
2006 was performed. Data from the last outpatient clinic attendance during 2006 
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was recorded. Once again, average values were calculated, allowing this data was 
to be compared with the average data obtained previously. Current medication use 
was recorded; this was compared to the recorded medication from their last 
attendance in the previous review. Patients who were no longer attending the clinic, 
but who had been included in the earlier assessment were not reviewed here, 
although record was made of these patients. 
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9.3 Statistical analyses. 
All data was assessed for normality of distribution. Parametric data was analysed 
using students’ t-test (matched or non-matched) where appropriate. Non-parametric 
data analysis was made using Mann-Whitney U Test. Comparison of use of 
medication was calculated using the test of significance on two independent 
proportions. Significance was taken to be a p value of <0.05. All data analysed using 
StatsDirect version 2.6.5., StatsDirect, Cheshire, WA14 4QA, UK. 
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9.4 Results. 
Between 1991 and 1996 three hundred and eighty-six patients attended at least 
once and had recorded biophysical data. The full details of the cohort are detailed in 
the table below. There were 214 patients of the original cohort still attending the 
clinic by the end of December 2006. These patients had an average duration of 
diabetes of 23.46 (SD± 8.06) years. There were 134 male patients (62.62%). 




1996* 386 - - - - 
2001 261 92 11 22 -125 




Of those that were no longer under the review of the clinic, five had died, their 
average age at death being 58.8 (SD± 12.78) yrs, and duration of diabetes 40.6 (SD 
±7.64) yrs. Thirty-four patients had either been discharged due to persistent non-
attendance (28 pts) or had had their care transferred to another diabetes clinic or 
consultant (6 pts). A further eight patients were lost to follow-up by the clinic. The 
HbA1c of this group at last recorded attendance was 9.33% ±1.4 (not significantly 
different from the 214 continued attendees, by Mann Whitney U Test p=0.21). 
 
9.4.2 Continued Attendees 
The exact data on the patients in 2001 has been published elsewhere238 The 214 
patients seen and reviewed in the year 2006 had an average age of 43.66 (SD 9.59) 
106 | P a g e  
 
yrs and an average duration of diabetes of 23.45 (SD 8.06) yrs. The data obtained in 
2001 was then compared with the most recent data to see if any significant changes 
had occurred in the intervening years. Table 9.4.2 shows the baseline data from 
both interval analyses and the statistical significance of any differences. The change 
in the values is also shown, expressed as a value relative to the 2001 data and 
demonstrates that small changes have occurred during the intervening period in 
these patients. The most apparent change occcurring in the mean total cholesterol 
values. Interestingly, both weight and BMI have seen small relative increases in the 
same time period, whereas the total insulin dose does not appear to have increased 
by the same proportion.  
The results also show that in the intervening period these 214 patients have seen a 
significant reduction in their mean HbA1c, diastolic blood pressure, urinary ACR and  
total cholesterol. There was however a significant increase in their weight and body 
mass index over the same period. No significant change could be found in  plasma 
creatinine levels or systolic blood pressure.There was no significant change in the 
units of insulin used per kilogram of body weight during this time. 
 
9.4.3 Guidelines 
During the period preceding the 2001 data collection, the guidelines for 
management of patients with T1DM in our clinic were roughly based around the 
results of the DCCT study; that is to say, we strived for tight glycamic control with 
the a target value of less <1% higher than the normal range. Blood pressure 
management was aimed at the then recommended guidelines of the recently 
published Joint British Societies Guidelines239 ; that is a systolic blood pressure of 
<130 mmHg and a diastolic blood pressure of <80 mmHg. Total cholesterol values 
were targeted at values of <5 mmol/l. Although no guidelines were published as 
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such, we aimed to maintain serum creatinine in the normal range, and as 
recommended screened annually for microalbuminuria (taken as >3.5 mg/mmol in 
the data used here). Both of these are clearly influenced by glycaemic control and 
the latter by blood pressure control 
Ideally we also tried to maintain a normal body weight and BMI by encouragement 
of a healthy diet and exercise. 
The proportion of the clinic patients achieving many of the targets in 2001 was less 
than ideal (shown in table 9.4.3).Gratifyingly there was a high proportion of patients 
reaching the blood pressure targets, and the majority of our patients had normal 
mean ACR and mean creatinine.The use of the estimated glomerular filtration rate 
(eGFR) was not in common clinical practice at that time. The proportions of the 
cohort achieving the targets in 2006 are also shown. Comparison of the two groups 
demonstrates the differences in proportion achieving the relevant targets. Although 
the target for systolic blood pressure had become lower over the review period, 
nearly two thirds of the cohort was still in the recommended range. The 
recommendation for diastolic blood pressure had remained the same, and the 
proportion of the cohort achieving it had increased from 84.58% to 93.93%. 
Similarly, even though the glycaemic target had dropped from <7% to <6.5%, more 
patients in the cohort were within the target range. It is noteworthy that the number 
of patients a normal BMI had decreased over the intervening period for 107 to 63. A 
clear change in prescription of medication had also occurred in the five years 
between the two guidelines. 
 
9.4.4  Medication 
The use of medication to achieve these targets was also reviewed. The data 
gathered here was from the declared medication at the time of the patients’ most 
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recent clinic visit up to Dec 31st 2001 and their declared medication at the last visit in 
2006. The guidelines in 2001 were more cautious in the treatment of cardiovascular 
risk factors in patients with T1DM, than perhaps current ones are. Most of the 
patients were on a pre-mixed biphasic regime of insulin administration, the type of 
insulin used was not accurately recorded and consequently we were unable to 
determine whether the newer analogue insulins were being used to any degree. 
Only small proportions of the clinc population were being treated actively for raised 
blood pressure, cholesterol or nephropathy as determined by a raised ACR. This 
data is shown in table 9.4.4  below. 
 
It is noticeable that an increase in the use of MDI insulin, ACE inhibitors/ARBs, 
Statins, other blood pressure medication and even Metformin (no patients were 
using metformin when assessed in 2001) had occurred over the review period.  
Following the review of the data in 2001, diabetes management underwent change. 
The contemporary guidelines suggested more aggressive management of 
cardiovascular risk factors, even the management of hyperlipdaemia in patients with 
T1DM was subject to a more aggressive approach, despite the wealth of evidence 
on this subject being for patients with type 2 diabetes. The most recent; that is up 
until the end of 2006, guidelines from the American Diabetes Association196 , and 
the Joint British Societies34 are given in table 9.4.5.  
It is possible to estimate the overall improvement in cardiac risk of these patients 
using a cardiovascular risk calculator. If we treat the average values of the two 
groups, as detailed in table 9.4.2,  as the risk factors then any potential improvement 
can be gauged. In this instance the risk calculator based upon the JBS2 guidance is 
used (http://cvrisk.mvm.ed.ac.uk/calculator/calc.asp). 
For the patient group reviewed in 2001 the following factors  were used: 
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 (Age- 44, Sex- male, Diabetes-yes, Systolic BP-126, Total Cholesterol-5.37) --
Probability of dying from cardiovascular disease in next 10 years is 1.1 % 
Assumption made that HDL=1.0.  
Whilst in the group reviewed in 2007: 
( Age-44, Sex-male, Diabetes-yes, Systolic BP-126, Total cholesterol- 4.62) -- 
Probability of dying from cardiovascular disease in next 10 years is 0.8%. 
Assumption made that HDL=1.0.   
Age was left the same in both groups to negate natural aging and smoking status 
was assumed to be non-smoker as only 30% of the groups were current smokers. 
This shows that even the marginal differences between the two analyses can 
contribute to a reduction in overall cardiovascular risk.  
As illustrated previously in Table 9.4.3, blood pressure targets were tighter than in 
2001, with a systolic  target of  less than 130 mmHg. Glycaemic targets were also 
tighter, aiming at levels less than 6.5%. Cholesterol targets were also lower with an 
optimal value of < 4.0 mmol/l.  
The results show that in a group of patients followed up in the same clinic for an 
extended period of time by the same diabetes team, small but statistically significant 
improvements in the biophysical measurements of disease can be made. These 
changes may well reflect a changing approach in the management of the risk factors 
for glycaemic control and cardiovascular disease over more recent years and result 
in reduction in the of risk of future cardiovascular events. 
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Table 9.4.2  All numbers are mean values for the cohort (n=214) in the years when 
reviewed. 
Measurement Patient cohort 2001 
Patient cohort 
2007 
Relative % Change 
since 2001 P value 
     
HbA1c 9.06 (± 14.35) 8.66 (± 1.43) -4.41 P = 0.0002 * 
Systolic BP 126.43 (± 6.56) 126.13 (± 18.97) -0.24 P = 0.8148 
Diastolic BP 73.55 (± 15.25) 67.38 (± 9.73) -8.39 P < 0.0001 * 
Microalbumin / 
Creatinine ratio 
5.82 (±21.84) 5.49 (± 16.26) -5.67 P = 0.0033 * 
Creatinine 93.70 (± 0.97) 96.24 (± 46.20) 2.71 P = 0.0909 
Total Cholesterol 5.37 (± 11.75) 4.62 (± 0.90) -13.97 P < 0.0001 * 
Weight 75.04 (± 3.41) 82.31 (± 14.79) 9.69 P < 0.0001 *  
BMI 25.32 (± 0.27) 27.72 (± 5.17) 9.49 P < 0.0001 * 
Insulin Units / Kg 0.75 (± 0.23) 0.79 (± 0.28) 5.33 P = 0.597 
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Table 9.4.3  * Significance taken as p <0.05. Values calculated by Mann-Whitney U 
test. 


















     
HbA1c < 7% 3.74 % (8) < 6.5% 5.14% (11) 
Systolic BP (mmHg) < 140  69.16 % (148) < 130  62.62% (134) 
Diastolic BP (mmHg) < 80  84.58 % (181) < 80  93.93% (201) 
Microalbumin /Creatinine 
ratio mg/mmol <3.5  77.10 % (165) <3.5  83.64% (179) 
Creatinine µmol/l < 120  95.79 % (205) < 120  93.93% (201) 
Total Cholesterol mmol/l < 5.0  37.38% (80) < 4.0  27.10% (58) 
Weight N/A N/A N/A N/A 
BMI Kg/m2 20-25  50.00% (107) 20-25  29.44% (63) 
Insulin Units / Kg N/A N/A N/A N/A 
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           Twice daily 
           Basal Bolus 
           Other 
 
62.61 % (134) 
33.18 % (71) 
4.21 % (9) 
 
33.17 % (71) 
65.42 % (140) 





ACE inhibitor/ ARB 
Statin 
26.16 % (56) 
12.15 % (26) 
45.34 % (97) 
59.81 % (128) 
<0.0001 
<0.0001 
Other Blood Pressure treatment 7.47 % (16) 22.43 % (48) <0.0001 
Metformin 0% 15.89% (34) <0.0001 
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Table 9.4.5 Comparison of ADA and JBS2 targets. 
Clinical Variable ADA targets 2005 JBS 2 Targets 2005 
HbA1c <7.0 % <6.5 % 
Blood Pressure <130/80 <130/80 
Total cholesterol <4.1 mmol/l <4.0 mmol/l 
LDL- Cholesterol <2.6 mmol/l < 2.0mmol/l 
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9.5 Discussion.  
Since the publication of the Diabetes Control and Complications Trial (DCCT) 
results healthcare professionals have strived, supported by good evidence, to 
improve the glycaemic control of patients with T1DM. This process has not always 
been easy, as many factors other than insulin use can influence the ability of the 
patient and the diabetes team to attain the recommended goals 160-163, 240, 241. 
Perhaps, as a consequence of this, as well as the holistic nature of diabetes care 
teams, recognition of other influential cardiovascular risk factors in the morbidity and 
mortality of patients with T1DM occurred early and was reflected in the management 
guidelines produced by leading professional bodies. In more recent years, an early 
intervention and aggressive management policy has been advocated in guidelines 
with the overall aim of reducing the complications of diabetes. 
Much as with the DCCT, it is important to assess if such aggressive 
recommendations are actually attainable in day to day clinical practice. Certainly, 
evidence demonstrates that sub selecting ‘at-risk’ groups within a clinic population, 
and intervening with focused and repeated targeting of the problem areas can 
improve outcomes in the short term, albeit in patients with type 2 diabetes.242, 243 
One might expect a comparable approach to be similarly effective in patients with 
T1DM.  
As effective as short term interventions may be, a sustained improvement in the risk 
factors is the ultimate goal; only by achieving these can improvements in morbidity 
and mortality hope to be effected. Our observations of a cohort of patients with 
T1DM, managed in the ’real-world’ to contemporary standards, show that over a five 
year period small but statistically significant improvements in the biophysical 
markers can be made. It is clear, however that these improvements are small, and 
come at no little cost; the relative amounts of medication used by the patients 
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increased significantly over the time period observed. If these improvements can be 
sustained and built upon, then the benefits to the patients in terms of improved 
health will be worth this aggressive approach. 
When outcomes improve, it is important to ask which intervention was responsible; 
the difficulty in this situation is identifying the particular intervention which resulted in 
benefit. For example, glycaemic control is about far more than prescribing insulin. 
Issuing a prescription for insulin is only the first step; it is clear that education of the 
patient, and indeed continued communication between healthcare professional and 
patient, is as important. The DARTS-MEMO study160 clearly demonstrated that 
prescriptions for insulin, for patients with T1DM, were not always completed as 
expected. It was suggested that up to 28% of the patients in this group had 
occasions of omission of insulin. If there was a singular reason for such omission 
then it may be easy to address but this is not the case.  
Our cohort demonstrated significant changes in their insulin use. A shift from the 
predominant use of biphasic pre-mixed insulin to a multiple dose injection regime 
was one of the more obvious changes that had occurred. This clinic does not and 
never has offered an insulin pump service. Could a simple change of insulin regime 
be responsible for the improvement seen in glycaemic control? It is unlikely that this 
could be wholly responsible, although some improvements in control have been 
reported244, other evidence would suggest no significant change245  occurs. The 
change to MDI in itself is not a clear matter because of the increased use analogue 
insulin, particularly with the multiple dose injection regimes. Less hypoglycaemia is 
reported to be experienced with analogue insulin use and the subsequent reduction 
in fear of hypoglycaemia could then allow a more aggressive dose titration policy 
and subsequent improvement in glycaemic control 108, 172, 175, 246, 247 although not all 
evidence supports this248. We feel that although improvements may be seen with 
changes to both multiple dose injections and analogue insulin and that this has 
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contributed to improved outcomes it is probably clinically more relevant to have 
regular useful contact with the patients and address any ongoing issues with self 
management to sustain any transient benefits. 
What then of improvements in the other biophysical markers of disease such as 
blood pressure and cholesterol measurements? We followed contemporary 
guidelines and managed cholesterol and blood pressure accordingly. It can be seen 
from our results that there were small, but significant improvements in both of these 
parameters, although there was no significant improvement in systolic blood 
pressure. The reason for the fall in diastolic pressure but not systolic pressure isn’t 
clear, but it is a well recognised phenomenon 249. The benefits of risk reduction, 
although not well demonstrated when lowering diastolic pressure alone, when 
compared to lowering both systolic and diastolic parameters, does remain 250.  
The results also show a significant fall in the total cholesterol over the two sample 
periods. There was no change in the dietary advice issued to these patients during 
this time. The approach of using statin therapy in this population is effective at 
lowering cholesterol, if a little controversial, with the suggestion that only those with 
overt nephropathy actually benefit from long term risk reduction 251, 252. In our group 
there was maintenance of mean serum creatinine values and no deterioration in the 
mean urinary microalbumim values, which may actually reflect good blood pressure 
control, given the known associations 27, 28. Aside from this, improvement in serum 
lipid profiles is also seen with improving glycaemic control.  
That said, even on the rather crude analyses used to estimate risk in this paper, it is 
possible to demonstrate an improvement in cardiovascular risk in the group. This is 
of course more relevant in the light of the findings from the EDIC follow-up group on 
cardiovascular risk36 and further meta-analysis253.  Of course, the cardiovascular-risk 
score only details the presence or absence of diabetes and does not relate it to a 
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value of HbA1c. The findings from the EDIC follow-up paper would suggest that 
intensive glycaemic control is also protective against cardiovascular events when 
compared to conventional glycaemic control such that, intensive treatment reduced 
the risk of any cardiovascular disease event by 42 percent and the risk of nonfatal 
myocardial infarction, stroke, or death from cardiovascular disease by 57 percent. 
The decrease in glycosylated haemoglobin values during the DCCT was 
significantly associated with most of the positive effects of intensive treatment on the 
risk of cardiovascular disease. 
What is clear however is the significant increase in the amount of medication 
required by the patients to achieve both blood pressure and cholesterol control. In 
the intervening period the use of medication to control both blood pressure and 
cholesterol increased dramatically. The pill-burden of patients with type 2 diabetes 
(T2DM) has been recognised for some time and is partially a factor in non-
concordance with medication use. Patients with T1DM may now also be facing a 
similar problem as the use of medication to control cardiovascular risk factors 
increases in this group. 
What also of the influence of guidelines for care which have changed over the 
period reviewed here? It is difficult to attribute overall improvements in care to a 
change in practice recommendations. The compliance with guidelines in a clinic 
setting is yet another variable and targets are individualised for each patient 201, 254, 
255.
 On reviewing our data improvements may be seen in the proportion of patients 
achieving these goals, although less achieve the tighter targets set more recently, 
the proportion achieving the preceding goal have increased significantly. This would 
suggest that an overall drive to attain newer targets has had an effect on general 
care. Further improvements may be seen in the current group should we re-examine 
them in three to five years time. 
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The recent change in approach to management of chronic disease in the community 
due to the implementation of the Quality outcomes Framework (QoF) in the UK has, 
along with the National Service Framework for Diabetes (NSF- Diabetes), served to 
bring uniformity to the delivery of diabetes care but whether the QoF system will 
lead to further gains in improving cardiovascular risk factors in patients with T1DM 
remains to be seen. It may be reasonable to suggest that the continuing care given 
by primary care physicians; the expert input which can only come from a specialist 
diabetes care team and continuing education and support of the patients with T1DM 
will improve all round care. The development of new drugs and technologies are 
welcomed but the demonstration of sustained benefit in this challenging group of 
patients should be clear before their introduction into clinical practice. In the 
meantime we strive to improve the outcomes of our patients with the most effective 
treatment and management available. Perhaps, a further review of this cohort in five 
years time may yield improved results. 
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10.  Hospital in-patients with diabetes: Increasing 
prevalence and management problems.   
 
M. Wallymhamed, S. Dawes, G. Clarke, S. Saunders, N. Younis and I.A. Macfarlane 
(Diabet Med 2005;22:107-9) 
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10.1  Introduction 
 
Approximately 3% of the United Kingdom population have diabetes mellitus and the 
prevalence is increasing256-258. Poor diabetes control is related to vascular 
complications259, 260 and patients are admitted to hospital twice as often and stay 
twice as long as those without diabetes261. Previous surveys indicate that 6–16% of 
hospital beds are occupied by a person with diabetes and management is often 
suboptimal213, 261-266. People with diabetes account for around 5% of total NHS 
resources and 9% of hospital costs262. In 1991  an audit, on a single day, of our 
hospital revealed that 7.0% of in-patients had diabetes and management was 
considered inappropriate in 20%213. Subsequently an in-patient diabetes liaison 
nurse was appointed and we repeated this audit in 2003 to assess current problems. 
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10.2  Methods 
 
The study was conducted in a large urban hospital in spring 2003. The hospital 
departments were unchanged from 1991, serving a population of approximately 400 
000 people (surgical, medical, gynaecology, obstetrics and psychiatry specialities). 
Some departments (Neurosciences, Head and Neck surgery) are regional (Greater 
Merseyside and North Wales). On one weekday, case records of all patients 
occupying inpatient beds were reviewed by a consultant diabetologist or specialist 
registrar and a diabetes specialist nurse. Patients with established diabetes and 
those newly diagnosed on this current hospital admission were identified. Patients 
with a raised blood glucose (> 11 mmol/l) this admission, but no previous diagnosis 
of diabetes were identified. Type 1 or Type 2 diabetes was diagnosed on clinical 
grounds. Diabetes details and treatments, primary reason for admission, speciality 
bed occupied and referrals to the hospital diabetes team (nursing or medical) were 
recorded. Appropriateness of diabetes care was agreed by the whole audit team 
and recorded, this was the same method used in the original 1991 audit. After 3 
months discharge letters (computerised data), of patients with a definite diagnosis of 
diabetes (previously and newly diagnosed this admission), were reviewed. The 
admission outcomes, length of hospital stay and if diabetes was mentioned on the 
discharge summary were recorded. 
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10.3  Results 
 
On the day, 1191 hospital beds were available for occupancy. Thirty-five were 
empty and 27 hospital case-notes were absent (e.g. patients in X-ray), leaving 1129 
notes for audit. One hundred and twenty-six (11.1%) had a definite diagnosis of 
diabetes (97%, 122pts Type 2, 3%, 4pts Type 1). Sixty-two per cent were in medical 
wards, 24% surgical wards, 114 previously diagnosed and 12 newly diagnosed this 
admission (Table 1). Another 13 patients had a raised random blood glucose (> 11 
mmol/ l) indicating possible diabetes. The primary reason for admission was 
diabetes related in 16/126 (12.6%) (8 hyperglycaemia, 1 ketoacidosis, 3 
hypoglycaemia, 3 foot ulcers, 1 cellulitis). Other admissions included 16 with 
macrovascular disease (e.g. myocardial infarction, heart failure, cerebrovascular 
accident, peripheral vascular disease). The admissions detailed above as 
ketoacidosis (1pt) and hypoglycaemia (3pt) occurred in those 4 patients with type 1 
diabetes. Clearly the bulk of hospital in-patient work in this daily snapshot consisted 
of patients with type 2 diabetes. The problems of metabolic decompensation in type 
1 diabetes are however highlighted by these admissions. 
 
 
10.3.1 Diabetes management and referrals to the diabetes team 
Six patients had been admitted that morning. Of the other 120 patients with definite 
diabetes, 33 (27.5%) had been referred to the diabetes team this admission (19 to 
specialist nurses, 4 to medical staff, 10 to both). Management was considered 
appropriate in 85 (71%), 32 of whom had previously been referred to the diabetes 
team. Management was considered inappropriate in 35 (29%) and only one of these 
had been referred. Inappropriate management included: patients with organ failure 
receiving metformin; high blood sugars with no treatment review or referral to the 
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team; omission of diabetes medication; inappropriate IV insulin regimens or blood 
glucose monitoring. In 62 (52%) patients no record of diabetic complications had 
been made and glycosylated haemoglobin (Hba1c) had been measured in only 29 
(24%) patients.  
The inappropriate use of intravenous insulin, either in dose or need of such 
treatment had been identified in another audit conducted around the same time. 
This audit had particular relevance to patients with type 1 diabetes who were 
admitted with DKA. It confirmed inadequate documentation, administration and 
monitoring of IV insulin and its subsequent effect on patients admitted with DKA. It 
led to the implementation of a DKA protocol within the hospital trust.  
 
10.3.2 Diabetes screening and follow up of raised random blood glucose 
Of 1129 records, 191 (17%) had no blood glucose measurement during this 
admission. Thirteen patients had raised random blood glucose (> 11 mmol/l) without 
a previous diagnosis of diabetes but this was written in the notes of only 3. The audit 
team advised repeat measurements and 9 patients subsequently had normal blood 
glucose levels. Blood glucose remained raised in one patient who subsequently died 
of a stroke. The other 3 patients did not have repeat measurements. Seven of the 
13 patients, including these 3, died in hospital. 
 
10.3.3 Three month follow-up 
Ninety eight of the 126 patients with diabetes had been discharged, 12 died in 
hospital, 3 had transferred to another hospital and 7 remained in hospital. The 12 
deaths included: malignancy [6], heart failure [4], myocardial infarction [1], and 
stroke [1]. Information on the outcome of 6 patients was not found. Discharge 
124 | P a g e  
 
summaries to Primary Care had been completed in only 90/119 (75%) and diabetes 
was not mentioned at all in 47% of these. 
Of the 4 patients with type 1 diabetes, all were discharged home without further 
consequence. Clinic follow up had been arranged in these cases. 
 
10.3.4 Length of hospital stay 
Median hospital stay for the 113 patients with diabetes with data available was 19 
days (range 1–300+). Median length of stay for patients who had been referred to 
the diabetes team was 18 days. During the month of the audit day, the mean length 
of stay for all hospital patients (with and without diabetes) was 10 days. 
 
10.3.5 Comparison with previous audit (1991) 
Between 1991 and 2003, the number of beds available decreased by 25%, 
particularly in medicine for the elderly, and bed occupancy increased from 83% to 
97%. The prevalence of diabetes increased from 7% to 11.1% (P < 0.01, Chi-
Square) and more had been referred to the diabetes team, 26% v 10% (P < 0.01). 
Diabetes management was considered inappropriate in 29%, more than in 1991 
(20%). Median length of stay for patients with diabetes had decreased slightly, 22 
days to 19 days (Table 10.1). 
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Table 10.1 Comparison of the findings of the 1991 and 2003 audits of hospital in-patients 
with diabetes 
 
 1991 (no. beds = 1596) 2003 (no. beds = 1191) 
 
Type 1 (n = 5) Type 2 (n = 88) Type 1 (n = 4) 
Type 2 (n 
=122) 
Age (years) 61 (26–66) 4 (34–94) 44 (24–66) 73 (34–97) 
Sex (M:F) 3 : 2 47 : 41 0 : 4 64 : 58 
Duration of diabetes (years) 10 (0–44) 7 (0.2–23) 25 (3–40) 4.0 (0–40) 
Diabetes treatment     
         Diet alone    35 (28%) 
         OHA’s    66 (52%) 
         Insulin only    19 (15%) 
         Insulin/OHA’s    6 (5%) 
Overall prevalence of 
diabetes in hospital (%) 7.0%  11.1%*  
Patients who had been 














Length of stay (days) 
(including 16 deaths in 
1991,12 deaths in 2003) 
 






OHA’s, oral hypoglycaemic agents. Results expressed as median (range) or (percentage). *1991 
survey v 2003 survey: P < 0.01 (χ2). 
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10.4  Discussion 
The audits (1991 and 2003) were on a single day and therefore are subject to 
random bias such as the severity of illness. Predictably the prevalence of in-patient 
diabetes has increased (7% to 11.1%, 97% Type 2) most being admitted for reasons 
other than diabetes. For patients with T1DM the prevalence and reasons for 
admission remained similar during the interval period of audit. As a whole this group 
of patients contributes little to the burden of inpatient diabetes care. However it is 
important, that since these admissions usually reflect metabolic decompensation, 
that the management is timely and correct.  
 
More patients are now referred to the diabetes team for management advice, mostly 
to the in-patient diabetes liaison nurse, not present in 1991. However most are still 
not referred, including newly diagnosed patients and those admitted with diabetes 
related complications. This is despite a widely distributed written policy for referral. 
Diabetes management was considered inappropriate in 29% of patients, only 1 of 
whom had been referred to the diabetes team. Early referral of many of these 
patients to a specialist nurse may influence quality of care and length of stay218, 219 
and clinic defaulters can be educated and screened for complications. We do of 
course recognise the risk of de-skilling the general nurse in using a specialist nurse, 
and it therefore important to maintain diabetes education for non-specialist staff. The 
recently introduced ‘Think Glucose’267 guidance aims to provide support in this area 
amongst many of its aims, and it draws much of its information from ‘Focus On: 
Inpatient care for people with diabetes’268. The UK National Service Framework for 
Diabetes: Standards Document 130 and Diabetes UK269  stress the important role of 
a multidisciplinary diabetes team in the care of in-patients. However for every 
person with diabetes to be reviewed at least once during each admission to this 
hospital, more specialist nurse time would be required. Currently we are developing 
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a new system of individual ward-based diabetes link nurses, who receive some 
specialist training in diabetes. This will help ensure that the in-patient diabetes 
guidelines are implemented and filter referrals to the specialist service. 
 
Various other deficiencies were revealed by this audit. HbA1c, which is helpful in 
deciding changes to treatment, had been measured in only 24% of patients with 
diabetes. There was also a failure to perform screening for diabetes with blood 
glucose measurements in 17% of all in-patients. Discharge summaries to Primary 
Care had been completed in only 75% of patients and diabetes was not reported in 
47%, an omission which can have an adverse effect on care after discharge. 
Previous studies also found this213, 264, 265. Diabetes was recorded in only 3 of the 12 
newly diagnosed patients’ summaries. These shortfalls are due to several factors. 
Compared to 12 years ago there are fewer hospital beds, increasing numbers of 
acute admissions, higher bed occupancy and pressure to rapidly discharge patients. 
In addition the reduction in junior doctors hours of work in the UK leads to lack of 
continuity of care and extra pressure on senior nursing and medical staff. There is a 
clear need for constantly educating and reminding junior doctors about the referral 
criteria, the in-patient guidelines and accurate discharge summary documentation. 
However guidelines alone will have only a small impact on the quality of care for in-
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11. Intravenous drug abuse and Type 1 diabetes: financial 
and healthcare implications    
 
S.A. Saunders, J. Democratis, J. Martin and I.A. Macfarlane 
Diabet Med 2004;21:1269-73. 




Type 1 diabetes (DM) has an incidence of approximately 16 per 100 000 people in 
the UK. It predominately presents in younger age groups and consequently results 
in a lifetime of insulin replacement and disease management. Good diabetes control 
decreases the risk of developing microvascular disease.1 Crucial in achieving good 
control is a motivated patient and regular input from a specialist diabetic team.  
Intravenous drug abuse (IVDA) can markedly disrupt a normal lifestyle and a healthy 
regular diet. If type 1 diabetes is also present, a major disruption to the regular 
routine of insulin injections and food intake often occurs. In recent years we have 
been aware of frequent hospital admissions by patients with type 1 diabetes who 
were also intravenous drug abusers (IVDA-DM). We therefore studied the 
healthcare problems and the financial costs of these hospital admissions in a group 
of patients admitted over a six-year period.  
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11.2 Methods  
The hospital admission and discharge coding system, which allows cross-
referencing of disease codes (ICD-10), was used to identify people with type 1 
diabetes and a history of intravenous drug abuse that had been admitted to a large 
University Teaching Hospital over a six-year period, January 1997 to December 
2002.The coding system was also used to identify admissions of IVDA patients due 
to misuse of opiates or psychoactive drugs. The diabetic patients usually failed to 
attend diabetes outpatient services and were often impossible to follow up after 
hospital discharge. Each of the IVDA-DM study group was then matched with two 
controls (DM) with no history of IV drug abuse that were selected from a register of 
patients with type 1 diabetes attending the hospital diabetes outpatient clinic, of the 
same sex, diabetes-duration and age; the matching was blinded to any further 
information such as HbA1c or hospital attendances. Both these groups were then 
compared to patients with a history of IVDA alone, for comparison of hospital 
admissions. For each patient (IVDA-DM) and control (DM) the following data was 
obtained from every available recorded measurement; HbA1c, creatinine, 
cholesterol, urine albumin (albustix), blood pressure, insulin dose, weight and body 
mass index. Mean values for each of these variables for the six-year period were 
then calculated. Also recorded at their last attendance or inpatient stay were details 
of micro or macrovascular disease: retinopathy and laser treatment, renal 
impairment, ischaemic heart disease, myocardial infarction, transient ischaemic 
attacks, cerebrovascular accident, peripheral vascular disease and other major 
illnesses. Finally, in December 2002, case notes were reviewed to record the 
number of deaths.  
The total number of inpatient admissions during the six-years of the study (critical 
care facilities or general medical/surgical ward) was also calculated and from this 
the financial cost to the Hospital Trust of these admissions was estimated. These 
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figures were discussed with and kindly reviewed by the finance directorate of this 
hospital trust to ensure accuracy. Attendance at the outpatient diabetes clinic was 
also noted. Data was obtained by review of hospital notes and the biochemistry 
laboratory data system. Local ethics committee approval was granted for this study. 
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11.3 Statistical Analyses 
Individual six-year means and then six-year mean values for the groups were 
calculated. For normally distributed variables, mean and standard deviation are 
quoted. For non-normally distributed variables; median and inter-quartile ranges are 
quoted. Parametric data were compared with unpaired t-tests and non-parametric 
data using the Mann-Whitney U test and for multiple group analysis the Kruskal-
Wallis method for no-parametric data was used; two-sided p-values are quoted for 
these. Significance was accepted at p values of <0.05. Analysis performed on 








Nine patients were identified who had both Type 1 diabetes and a history of IVDA 
and were compared to eighteen matched controls. The demographic data from the 
two groups is shown. (Table 11.1) These were in turn compared to 200 IVDA control 
patients (the total number of patients identified by the coding system between 1997 
and 2002) who were unmatched to the other groups. The IVDA-DM group contained 
one patient who died in the year 2000 and therefore did not have a data set for the 
full six years. 
The six-year data (table 11.1) show large and significant differences between the 
three groups in inpatient days per year, in both acute medical beds (IVDA-DM 
30.4±29.2 days vs IVDA controls 4.9±5.19 vs DM controls 1.1±1.7; p<0.0001) and 
critical care facilities (IVDA-DM 1.1±1.6 days vs IVDA controls 0.09±1.2 vs DM 
controls  0; p=0.014). No significant differences between the two groups could be 
detected in HbA1c, serum creatinine, cholesterol, diastolic blood pressure, and 
insulin dose per kilogram in 1997 or 2002. 
 The 9 IVDA-DM patients spent a collective 1513 days in hospital (including critical 
care facilities) over a six-year period, which approximates to 168 days/patient over 
six years. In comparison, the IVDA control group of 200 patients spent a total of 
5844 days in hospital in six years, approximating to 29 days per patient over 6 years 
(including critical care admissions). The DM control group spent a total of 109 days 
in hospital, none of these in critical care facilities, approximating to 6 days per 
patient over the 6-year study period. The commonest cause for admission in the 
IVDA-DM group was diabetic ketoacidosis, the rate being 25-fold higher than in the 
DM controls (Table 11.2). Other common problems were in 6 patients who had, 
often prolonged, admissions related to the injection of drugs into their groins (major 
deep vein thrombosis or groin abscesses). Three groin abscesses required formal 
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incision and drainage, with one patient subsequently dying as a result of septic 
complications in 2002. The majority (>90%) of admissions for the IVDA controls 
were due to thrombo-embolic disease (DVT/PE), abscess treatment or localised 
infections e.g. Cellulitis. 
By final case note review in December 2002, 5 of the 9 IVDA group had died. Three 
deaths occurred out of hospital whilst the remaining two occurred during inpatient 
stays, one during an admission for diabetic ketoacidosis, one the result of septic 
complications of a groin abscess. In one of the out of hospital deaths, a patient was 
found dead at home after recent release from prison, dying as a result of a possible 
drugs overdose or not taking insulin. Information on the two remaining deaths was 
not available. 
The attendance rate at diabetes outpatient appointments was very poor in the IVDA-
DM group and the reasons included; some of these patients already being 
inpatients, being in prison (at least 3 of this group had spent significant time in 
prison during the study period), or having no fixed abode. Seven of the 9 IVDA-DM 
group were receiving opiate (methadone) replacement treatment (mean dose 55 
millilitres (1mg/1ml) in 2002) compared to none of the control group. Interestingly the 
control group, who did not abuse intravenous drugs, admitted the use of cannabis (2 
controls) and cocaine use (in one). A significant proportion of the IVDA group were 
also receiving methadone treatment (mean dose unavailable). 
The IVDA-DM group usually defaulted from clinic follow-up, but their 
inpatient records had more documented retinopathy than the control group and 
attended for laser treatment less frequently (Table 11.3). They also had more 
macroalbuminuria and painful neuropathic symptoms. No IVDA-DM patient had 
documented cardiovascular disease. 
Using figures from the financial year 2000-2001, mean daily bed costs for both acute 
hospital beds and critical care beds can be estimated. There was a huge difference 
135 | P a g e  
 
in the cost of these admissions between the two groups. Estimated mean hospital 
inpatient admission costs, per patient per year, were IVDA-DM  £6769 vs IVDA 
controls £1100 vs DM controls £213, (table 11.4.) Estimated total admission costs 
over the six-year study period were: £365 519 IVDA-DM vs £1 320 534 IVDA 
controls vs £22 999 DM controls. These figures do not take into account any 
investigation or treatment costs during the patients’ admissions. 
 




This study shows that a small group of type 1 diabetic patients can make huge 
demands on hospital healthcare services, by repeated admissions with serious 
medical and diabetic problems associated with IV drug abuse and omission of 
insulin. Frequent hospital admissions have previously been highlighted in the non-
diabetic IVDA population 270,271 and are again well demonstrated here. The majority 
of the admissions reported here were due to problems of diabetes control, mainly 
diabetic ketoacidosis (DKA) as opposed to the problems associated with drug use 
alone.  Hospital surveys of DKA indicate a mortality rate of between 2-5%272,273 and 
there was one death in this study group during such an admission. Predictably there 
was also an increased rate of admission for problems that were related to 
intravenous drug abuse 274,275, such as deep vein thrombosis and groin or limb 
injection site abscesses. One third of the IVDA-DM group underwent incision and 
drainage or formal debridement of groin/limb abscesses whilst inpatients. One of 
these patients had an admission lasting 126 days as a result of an abscess, which 
eventually contributed to that patient’s death. Similar problems were also seen in the 
IVDA control group who had numerous admissions like this. The average cost of 
these admissions per patient per year was more than 37 fold higher than the DM 
control group and 6 fold higher than IVDA controls. These patients also occupied 
valuable operating-theatre and radiology department time. This increases the overall 
cost of these admissions; something that our figures do not show. The audit also 
showed that the IVDA-DM group often failed to attend the diabetic outpatient service 
after hospital discharge It is estimated that between 4 and 18% of diabetic patients 
fail to attend their regular follow-up appointments 161,163, but the IVDA-DM group 
failed to attend the majority of their diabetes clinic appointments. Many 
appointments were missed because the patient was unable to be contacted, 
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probably because they had no fixed abode. A number of the IVDA-DM patients 
spent long periods of time in prison during the study period, also a problem with the 
IVDA controls, which also made them unavailable for clinic attendance276, 277. 
Several also had admissions to other hospitals in the region. 
The IVDA-DM group had a higher prevalence of microvascular complications than 
the DM control group. This occurred in spite of overall similar glycaemic control 
(HbA1c). Possible explanations for this include the high rate of smoking in the IVDA-
DM group (100% vs 38%), which is known to accelerate the development of 
microvascular complications278. Also the IVDA-DM group also weighed significantly 
less than the DM control group. No data on this was available for the IVDA controls. 
This is probably the result of inadequate nutrition and the under-use or missed 
insulin injections and no doubt the main reason for the high rate of admissions due 
to DKA. Many of these patients admitted openly omitting insulin for several days, 
either because they had forgotten or because they had been unable to collect a 
prescription. The high mortality rate after 6 years in the IVDA group (5/9) compared 
to no deaths in the controls is perhaps predictable. These patients intravenously 
inject potentially lethal doses of opiate drugs and also omit insulin, risking fatal DKA.  
The current literature contains little on the problems associated with drug abuse in 
type 1 diabetes 279 and no study on the problems associated with the intravenous 
drug use. Also the rate of substance misuse in the general population is not clear, 
as it tends to be non-declared. Attempts have been made to quantify the degree of 
substance misuse in hospital admissions 280, overall drug misuse occurring in 
around 5%, with intravenous drug abuse occurring in just over 1% of admissions. 
Previous estimates have been made of the prevalence of intravenous drug abuse in 
Liverpool 281 and a rate of 16.9 per 1000 in the 15-29 year old age group is quoted. 
The nine IVDA patients reported represent 9.5 % of the 15-29 year old type 1 
patients (n= 94) attending this hospitals’ diabetes clinic. 
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It is likely that other urban areas with similar sized hospitals would have a similar 
population of IVDA diabetics with repeated admissions. We accept however, there 
may be a small population of similar patients who do not suffer frequent admissions 
as a result of problems related to either IVDA or diabetes, but since this area has 
not been studied previously, it would be impossible to say one way or another. We 
therefore feel that this data is of importance in helping to define the size of the 
problem. On extrapolating our figures it is possible that 10 chronic IVDA type 1 
diabetics may occur in a population of 400 000. This may mean 1250 chronic IVDA 
type 1 diabetic patients could exist nationally. The cost to the NHS of managing 
these patients may be in the order of £9 million per year.  
Is it possible to improve the situation and reduce the mortality? The frequency and 
length of admissions are a major problem and reducing these would allow valuable 
resources to be spent elsewhere and more hospital beds made available for other 
patients. To prevent DKA directly supervised insulin therapy may help, much like 
observed administration of methadone at pharmacies or drug addiction clinics. 
However, this would require dedicated hostel accommodation with trained staff in 
diabetes management. Most of our IVDA-DM group had no fixed abode and a hostel 
could provide a short-term housing bridge and also allow specialist nurse and 
medical input into diabetes management and drug rehabilitation. 
The incidence of type 1 diabetes is increasing, and intravenous drug abuse 
continues unabated. It is therefore likely intravenous drug-abusing type 1 diabetics 
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Table 11.1.  Biochemical and physical variables of control and study groups. 
Overall Mean 
value for data 
1997-2002* 
IVDA-DM DM  (control) 
IVDA 
(control) Significance 
Number of patients 9 (2 female) 18 (4 female) 200 (69 female)  
Age in Dec 2002  
(years) 33.3 ± 3.16 33.1± 4.44 35.5 ± 5.18 NS (KW) 
Duration of Diabetes 
in Dec 2002 (years) 13.7 ± 4.4 14.1 ± 4.7 NA NS 
HbA1c (%) 10.2 (IQR 1.96) 9.1 (IQR 2.34) NA P = 0.061 (MW) 
Serum Creatinine 
(µmol/l) 93.0 ± 15.3 94.6 ± 22.3 NA NS 
Cholesterol (mmol/l) 4.8 ± 1.4 5.3 ± 1.0 NA NS 
Systolic Blood 
Pressure (mmHg) 118.2 ± 12.9 134.7 ± 13.8 NA P = 0.006 
Diastolic Blood 
Pressure (mmHg) 73.5 ± 11.2 73.6 ± 7.9 NA NS 
Weight (kg) 64.2 ± 12.0 78.4 ± 12.3 NA P = 0.012 
Inpatient days/ yr/ 
patient 
(Over 6 yrs) 
30.4 ± 
20.23*,** 1.1 ± 1.7 4.87± 5.19* 
P < 0.0001*,** 
(KW) 
Inpatient days in 
ITU/HDU/yr (Over 6 
years) 
1.1 ± 1.6*,** 0 0.09 ± 1.07 




dose (mls) N=7 46.3 ± 21.2 0 
Data not 
available P = 0.0008 (MW) 
Admitted smoking 




attendance / yr (over 
6 yrs) 
0.3 ± 0.6 1.2 ± 0.7 NA P = 0.0086 
Insulin dose u/kg 
1997 0.7 ± 0.2 0.7 ± 0.2 NA NS 
Insulin dose u/kg 
2002 1.0 ± 0.2 0.8 ± 0.2 NA NS 
 KEY: Data quoted as mean (standard deviation), or median (inter-quartile range): IQR- Inter-quartile range, ND- 
Not determined, NS- Not significant, KW- Kruskal-Wallis analysis for non-parametric data. MW – Mann-Whitney 
analysis for non-parametric data. P values significant at <0.05     
    All recorded data for the study period for each patient was calculated as a 
mean value, a mean value for each variable was then calculated to gain the group mean value.  
* Group significantly different from DM control, ** Group significantly different from IVDA control 
140 | P a g e  
 
Table 11.2  Total separate hospital admissions for diabetes related and non-
diabetes problems over 6-year period 1997-2002 in University Hospital Aintree. 
 DKA Hyperglycaemia Hypoglycaemia Other Problems 
DM 
Controls (n=18) 
2 1 0 9 
IVDA 
Controls (n=200) 
0 0 0 638 
IVDA-DM 
(n=9) 
53 18 2 45 
 
Table 11.3  Microvascular and macrovascular complications, where these details 
had been recorded in clinical notes 
Key: Retinopathy =any retinopathy not having had laser treatment, Macroalbuminuria as  






























NA NA NA NA 0.05% 5.0% 
IVDA-DM 
(n=9) 
44 % 11 % 33 % 44.4  % 0 % 55.5  % 
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Table 11.4  Admissions and costs of admission of control and study groups. 
































5844 110 1 209 874 110 660 1 320 534 1100 
IVDA-DM 
(n=9) 
1513 46 319 243 46 276 365 519 6769 
Key: Costs of ward bed is calculated on an average day bed rate financial year 2000-
2001(£211), Critical Care (ITU/HDU) beds calculated on daily bed rate (£1006) for same 
financial year. 
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12.  Discussion and Further studies 
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The studies in this thesis demonstrate that the management of patients with T1DM 
is a complex medical issue. This is a lifelong disease dependent on constant 
medication use to maintain health. Maintaining health is the minimum goal for 
diabetes care, as optimally, care should provide the patients with a complication-free 
life comparable to that of people without diabetes. 
There are of course many barriers to achieving this and such barriers are not simple 
to address. They are wide-ranging and some, as discussed in the literature, are not 
within the realm of outpatient medical care; falling more within the remit of political, 
economic and social areas. Since, however, the opportunity to deliver optimum 
medical care exists within the outpatient setting, then diabetes care teams should 
strive to engage and involve the patients, provide support and education where 
needed and offer the most suitable treatments available to maximise health and 
lower the risk of future complications. The real world delivery of such ideals remains 
a challenge. 
Whilst outpatient care characterises most of the management issues of patients with 
T1DM a significant number require inpatient care, particularly for acute metabolic 
disturbances. Also as outcomes improve, diseases of older age emerge. Clearly, 
ensuring optimal glycaemic control, timely intervention and treatment of 
complications and facilitated discharge is a service best performed by specialists 
with an interest in diabetes. The provision of such services within an acute setting, 
that attain standards of management and the education of non-specialist teams, 
requires continuation and expansion to achieve the ideals of optimum care. 
Regarding the future; the evidence for managing glycaemic and cardiovascular risk 
has accumulated. The implementation of such measures is becoming increasingly 
more important. The social context of medical care and the knowledge, 
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understanding and engagement of the patient become significant in determining 
how effective such treatments can be. 
It is critical to direct further studies into how treatment can be delivered effectively in 
the real world to patients with diabetes. Developments in forms of medication and 
their delivery, as well as methods of engaging with patients in the clinic setting 
should be assessed and audited to see if improvements can be made. Auditing 
current practice is fundamental to good clinical governance and to delivering 
optimum care.  The goal for future diabetes practice is high quality care delivered 
with optimum effectiveness.  
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